Operational Excellence
Annual Report
Laporan Tahunan
2013
Operational Excellence
Restrukturisasi Organisasi
Restrukturisasi organisasi bertujuan untuk efisiensi dan efektivitas, yang diselaraskan
dengan kebutuhan pengembangan bisnis dan tujuan Perseroan.
Restructuring Organization
Restructured organization is intended to efficiency and effectiveness harmonized
with the requirement of business development and goal of the Company.
KINERJA KAEF
KAEF Performance
Penjualan
meningkat
Sales increased
16,44%
Penjualan meningkat
16,44% dari Rp3,73
triliun pada tahun 2012
menjadi Rp4,35 triliun
pada tahun 2013
t
jumlah ase
t
ka
g
menin
reased
assets inc
tal
to
19,05%
meningkat
Jumlah Aset
Rp2,08
ri
19,05% da
Rp2,47
di
triliun menja
n 2013
hu
triliun pada ta
increased
Total Assets
Rp2.08
19.05% from
to
trillion in 2012
13
20
in
on
illi
tr
Rp2.47
A KAS
SETAR
&
S
A
K
gkat
menin
IVALENT
SH EQU
A
C
&
cash
ASED
INCRE
24,53%
Kas
n Setara
Kas da
3%
,5
kat 24
mening
iliar
m
316,50
dari Rp
2
1
0
2
hun
pada ta
5
,1
4
9
i Rp3
menjad
n
u
h
ta
ada
miliar p
2013
h
nd Cas
Cash a
sed
a
nt incre
Equivale
1
3 6.50
from Rp
24.53%
2012 to
billion in
in
5 billion
Rp394.1
2013
Sales increased
16.44% from Rp3.73
trillion in 2012 to
Rp4.35 trillion in 2013
Kapitalisasi
Pasar Saham KAEF menjadi
market capitalization
of KAEF stock became
Rp3,28 triliun
Kapitalisasi Pasar Saham KAEF menjadi
Rp3,28 triliun per 31 Desember 2013
Market Capitalization of KAEF Stock
became Rp3.28 trillion
per December 31, 2013
h
Margin Laba Bersi
turun sebesar
gin
Net Profit Mar
nt
ou
decreased am
0,55%
h
Margin Laba Bersi
dari
%
55
turun sebesar o,
12
20
n
hu
5,51% pada ta
2013
n
hu
ta
enjadi 4,96% pada
decreased
Net Profit Margin
m 5.51%
fro
amount 0.55%
in 2013
%
in 2012 to 4.96
BEBAN
POKOK
PENJU
ALAN
COST O
menin
F GOO
gkat
D SOLD
INCRE
ASED
1,75%
Beban
Pokok
Penjua
mening
lan
kat 1,7
5% dari
68,53%
pada ta
hun
2012 m
enjadi 7
0
,2
8%
pada ta
hun 20
13
Cost O
f Good
So
increas
e 1.75% ld
from
68.53%
in 2012
to
70.28%
in 2013
LABA BE
RSIH
mening
kat
NET PRO
FIT increased
4,59%
Laba Bers
ih mening
kat
4,59% da
ri Rp205,1
3
miliar pad
a tahun 2
0
1
2
menjadi R
p214,55
miliar
pada tah
un 2013
Net Profi
t increase
d
4.59% fro
m Rp205
.1
3
billion in 2
012 to
Rp214.5
5 billion in
2013
02
Restrukturisasi Organisasi
Restructuring Organization
03
Ikhtisar Keuangan
Financial Summary
2013
2012
2011
2010
2009
Neraca
Kas
Piutang Dagang
Total Aset Lancar
Total Aset Tetap
Total Aset
Utang Usaha
Total Kewajiban Lancar
Total Kewajiban Tidak Lancar
Total Kewajiban
Jumlah Ekuitas
Jumlah Investasi
Modal Kerja Bersih
Balance Sheet
Cash
Account Receivable
Total Current Asset
Total Fixed Asset
Total Assets
Account Payable
Total Current Liability
Total Non-Current Liability
Total Liability
Total Equity
Total Investment
Net Working Capital
394.150
546.576
1.810.615
498.644
2.471.940
477.892
746.123
101.462
847.585
1.608.225
199.269
1.064.492
316.498
458.728
1.505.798
449.140
2.076.348
341.133
537.184
97.630
634.814
1.426.497
81.802
968.614
199.386
384.037
1.263.030
426.720
1.794.400
284.234
459.694
82.043
541.737
1.252.660
42.334
803.336
265.446
357.712
1.139.549
413.197
1.657.292
300.987
469.823
73.435
543.257
1.114.034
38.353
669.726
163.821
304.591
1.020.884
402.062
1.565.831
357.286
510.854
59.662
570.516
995.315
34.078
510.030
4.348.074
1.292.152
1.042.619
284.125
214.549
38.63
3.734.241
1.175.167
912.599
278.284
205.133
36,93
3.481.166
1.038.016
816.012
232.007
171.765
30,93
3.183.829
904.519
758.321
178.611
138.716
24,98
2.854.058
788.250
676.317
99.730
62.507
11,25
Rasio-Rasio Keuangan
Imbal Hasil Ekuitas
Imbal Hasil Aset
Margin Laba Kotor
Rasio Operasi
Margin Laba Bersih
Rasio Perputaran Aset
Rasio Lancar
Rasio Cepat
Rasio Hutang Jangka Panjang
Rasio Kewajiban Terhadap Jumlah Aset
Rasio Kewajiban Terhadap Ekuitas
Financial Ratios
Return On Equity
Return On Asset
Gross Profit Margin
Operating Ratio
Net Profit Margin
Asset Turnover Ratio
Current Ratio
Quick Ratio
Long Term Debt Ratio
Liability to Total Asset Ratio
Liability to Equity Ratio
13.34%
8.68%
29.72%
95.07%
4.93%
191.20%
2.43
1.57
11.97%
34.29%
52.70%
14,38%
9,88%
31,47%
94,51%
5,49%
179,66%
2,80
1,82
15,38%
30,57%
44,50%
13,71%
9,57%
29,82%
95,07%
4,93%
201,72%
2,75
1,76
15,14%
30,19%
43,25%
12,45%
8,37%
28,41%
95,64%
4,36%
197,56%
2,43
1,60
13,52%
32,78%
48,77%
6,28%
4,00%
27,62%
97,81%
2,19%
189,75%
2,00
1,14
10,46%
36,30
57,32%
350 M
300 M
250 M
200 M
150 M
100 M
50 M
Jan
04
Feb
Mar
Apr
May
Jun
2012
Jul
Aug
Sep
Oct
Nov
Dec
Bulan
Month
Harga Pasar
Market Price
Tertinggi
Highest
Terendah
Lower
Terakhir
Closing
(Rp)
(Rp)
(Rp)
January 2012
475
320
Volume
(unit)
470
164.187.500
Nilai
Value
Frekuensi
Frequency
(Rp)
(x)
65.618.077.500
Kapitalisasi Pasar
Market
Capitalization
(Rp)
7.311
2.610.380.000.000
February
480
415
420
103.915.500
46.926.042.500
7.315
2.332.680.000.000
March
470
415
440
93.977.000
42.014.122.500
6.149
2.443.760.000.000
April
680
440
620
275.984.000
156.419.282.500
10.430
3.443.480.000.000
May
640
480
490
94.471.500
51.751.372.500
5.133
2.721.460.000.000
June
540
420
520
56.300.000
27.424.557.500
3.802
2.888.080.000.000
July
560
460
540
82.878.000
41.836.252.500
4.530
2.999.160.000.000
August
550
475
480
73.277.000
36.977.147.500
5.387
2.665.920.000.000
September
530
465
510
68.617.000
34.290.720.000
4.203
2.832.540.000.000
October
560
490
495
155.888.500
81.581.840.000
6.374
2.749.230.000.000
November
760
480
710
356.892.000
232.234.475.000
12.200
3.943.340.000.000
December
790
590
740
150.656.000
110.595.465.000
5.604
4.109.960.000.000
1.677.044.000
927.669.355.000
78.438
228.826.500
204.015.095.000
7.751
Total
January 2013
1.050
710
1.030
5.720.620.000.000
February
1.140
970
1.090
164.549.500
173.411.465.000
8.250
6.053.860.000.000
March
1.160
1.030
1.080
175.271.500
191.570.965.000
13.433
5.998.320.000.000
April
1.090
960
990
94.964.500
96.641.465.000
6.022
5.498.460.000.000
May
1.040
890
960
116.944.500
113.346.465.000
7.149
5.331.840.000.000
June
980
840
890
49.458.500
44.953.415.000
4.125
4.943.060.000.000
July
910
790
790
22.850.500
19.658.215.000
2.558
4.378.660.000.000
August
810
460
495
76.763.500
41.238.545.000
9.485
2.749.230.000.000
September
670
420
550
94.478.000
51.744.732.500
5.800
3.054.700.000.000
October
720
520
630
56.331.000
34.805.015.000
3.862
3.449.020.000.000
November
640
480
510
46.586.000
26.214.622.500
3.276
2.832.540.000.000
December
590
495
590
45.656.500
24.422.450.000
2.730
3.276.860.000.000
1.172.680.500
1.022.022.450.000
Total
Harga Saham/
Market Price
Volume
1200
1000
800
600
400
200
0
Jan
Feb
Mar
Apr
May
Jun
2013
Jul
Aug
Sep
Oct
Nov
Dec
05
Daftar Isi
Content
Profil Perseroan
Company Profile
07
36
10
38
13
Laporan Direksi
Report of Board of Directors
41
14
Tinjauan Manajemen
Management Review
46
Struktur Organisasi
Organizational Structure
22
49
23
54
26
Tinjauan Keuangan
Financial Review
59
Profil Direksi
Profile of The Board of Directors
30
65
Profil Saham
Profile of Shares
34
67
06
Profil Perseroan
Company Profile
Sekilas Kimia Farma
Kimia
Farma
adalah
perusahaan
industri
farmasi pertama di Indonesia yang didirikan
oleh Pemerintah Hindia Belanda tahun 1817.
Nama perusahaan ini pada awalnya adalah NV
Chemicalien Handle Rathkamp & Co. Berdasarkan
keputusan nasionalisasi atas eks perusahaan
Belanda di masa awal kemerdekaan, pada tahun
1958, Pemerintah Republik Indonesia melakukan
peleburan sejumlah perusahaan farmasi menjadi
PNF (Perusahaan Negara Farmasi) Bhinneka
Kimia Farma. Kemudian pada tanggal 16 Agustus
1971, bentuk badan hukum PNF diubah menjadi
Perseroan Terbatas, sehingga nama perusahaan
berubah menjadi PT Kimia Farma (Persero).
Alamat/Address
Berbekal
pengalaman
selama puluhan
tahun, Perseroan
telah berkembang
menjadi
perusahaan
dengan pelayanan
kesehatan
terintegrasi di
Indonesia.
With decades of
experience, the
Company has
developed into
a company with
integrated health
service in Indonesia.
07
Profil Perseroan
Company Profile
I CARE
menjadi acuan/
pedoman bagi
Perseroan dalam
menjalankan
usahanya,
untuk berkarya
meningkatkan
kualitas hidup
dan kesehatan
masyarakat.
ICARE
as the reference/
guidelines for the
Company to carry out
its business, produce
to improve the quality
of life and public
health.
08
Budaya Perusahaan
Corporate Culture
Innovative
Budaya berpikir out of the box, smart, dan kreatif
untuk membangun produk unggulan
Innovative
Think out of the boxes, smart, and creative to build
leading products
Customer First
Mengutamakan pelanggan sebagai mitra kerja
Customer First
Put priority on customers as a working partner
Accountability
Dengan senantiasa bertanggung jawab atas amanah
yang dipercayakan oleh perusahaan dengan
memegang teguh profesionalisme, integritas dan
kerja sama
Accountability
With everlastingly responsible for the mandate
entrusted by the company with hold professionalism,
integrity and cooperation
Responsibility
Memiliki tanggung jawab pribadi untuk bekerja tepat
waktu, tepat sasaran dan dapat diandalkan, serta
senantiasa berusaha untuk tegar dan bijaksana
dalam menghadapi setiap masalah.
Responsibility
Having personal responsibility to work on time, on
target and reliable, and continually seeks to stand
firm and wise in facing any problem.
Eco-Friendly
Menciptakan dan menyediakan baik produk maupun
jasa layanan yang ramah lingkungan.
Eco-Friendly
Create products or services and provide good
services environmentally friendly
Visi Perseroan
Company Vision
Misi Perusahaan
Company Mission
Jasa penunjang
lainnya termasuk
pendidikan,
penelitian dan
pengembangan
sejalan dengan
maksud dan tujuan
Perseroan, baik
yang dilakukan
sendiri maupun
kerja sama dengan
pihak lain.
Other supporting
services including
education, research
and development in
line with the purposes
and objectives
of the Company,
either individually
conducted or
collectively by other
parties.
09
Profil Perseroan
Company Profile
15 Maret 2013
PT Kimia Farma
Diagnostika menerima
Sertifikat ISO 9001
PT Kimia Farma
Diagnostika got ISO
9001 Certificate
3 April 2013
Rapat Umum Pemegang Saham
PT Kimia Farma Trading &
Distribution dan PT Kimia Farma
Apotek di Kantor Pusat Perseroan,
Jakarta
General Meeting of Shareholders
PT Kimia Farma Trading &
Distribution and PT Kimia
Farma Apotek at Head Office of
Company, Jakarta
Maret 2013
April 2013
27 Mei 2013
Penandatanganan Nota
Kesepahaman antara Perseroan
dengan Badan Pengkajian
dan Penerapan Teknologi
(BPPT) tentang Penelitian dan
Pengembangan Produk, di Kantor
Pusat Perseroan, Jakarta
The signing of Memorandum
of Understanding between
Company and Technology
Analysis and Application Board
concerning Product Research and
Development, at Head Office of
Company, Jakarta
10
27 Mei 2013
Penandatanganan Nota
Kesepahaman antara Perseroan
dengan PT Gama Multi Usaha Mandiri
tentang Pemasaran, Distribusi dan
Pengembangan Produk, di Kantor
Pusat Perseroan, Jakarta
The signing of Memorandum of
Understanding between Company
and PT Gama Multi Usaha Mandiri
concerning Marketing, Distribution
and Product Development, at Head
Office of Company, Jakarta
10 April 2013
Rapat Umum Pemegang Saham Perseroan Tahun Buku
2012 di Hotel Kempinski, Jakarta
General Meeting of Shareholders of Company for Fiscal Year
of 2012 at Kempinski Hotel, Jakarta
Mei 2013
27 Mei 2013
Penandatanganan Nota
Kesepahaman antara Perseroan
dengan Sekolah Tinggi Farmasi
ITB tentang Penelitian dan
Pengembangan Produk-Produk
Farmasi dan Herbal, di Kantor Pusat
Perseroan, Jakarta
27 Mei 2013
Penandatanganan Perjanjian
Kerja Sama antara Perseroan
dengan BATAN tentang
Perpanjangan Perjanjian Kerja
Sama Pengembangan Produk
Radiofarmasi, di Kantor Pusat
Perseroan, Jakarta
20 Mei 2013
Direksi Perseroan melaksanakan Gerakan Direksi Mengajar bertepatan dengan Hari Kebangkitan Nasional dan dilaksanakan secara serentak di beberapa kota
seperti Makassar, Jakarta, Pematang Siantar, Purwakarta dan Boyolali.
Board of Directors of the Company shall conduct Teaching Director Movement coinciding with National Awakening Day and be simultaneously conducted in
some cities such as Makassar, Jakarta, Pematang Siantar, Purwakarta and Boyolali.
Juni 2013
4 Juli 2013
Perseroan merambah
pasar internasional
dengan membuka
Apotek Kimia Farma
yang pertama di
Malaysia.
12 Juli 2013
Penandatanganan Kontrak Penjualan Produk
Perseroan senilai US $ 11.654.876 atau sekitar
Rp110 miliar antara Direktur Utama Perseroan,
Rusdi Rosman dengan Wakil Perdana Menteri
Republik Demokratik Timor Leste, Fernando
Lasama de Araujo di Timor Leste.
Juli 2013
Agustus 2013
4 Juni 2013
Penandatanganan Nota Kesepahaman antara Perseroan
dengan Badan Penelitian dan Pengembangan Kementerian
Kesehatan (Balitbangkes) RI tentang Pengembangan
Saintifikasi Jamu di Kantor Pusat Perseroan, Jakarta
The signing of Memorandum of Understanding between
Company and Research and Development of Ministry of
Health of the Republic of Indonesia concerning Herbal
Science Development at Head Office of Company, Jakarta
27 Agustus 2013
Penandatanganan Addendum antara Kementerian Riset dan Teknologi dengan 23
Instansi tentang Kesepakatan Bersama Sinergi Penelitian, Pengembangan Vaksin dan
Bahan Baku di Taman Mini Indonesia Indah, Jakarta.
The signing of Addendum between the Ministry of Research and Technology with 23
Agencies concerning Joint Agreement of Research Synergy, Vaccine Development
and Raw Materials in Taman Mini Indonesia Indah, Jakarta.
4 Juli 2013
Kunjungan Kerja Wakil Menteri Kesehatan Republik Demokratik
Timor Leste ke Kantor Pusat Perseroan didampingi Direktur
Jenderal Bina Kefarmasian Kementerian Kesehatan RI
Working Visit of Vice Minister of Health of Republic of Democratic
of Timor Leste to Head Office of Company accompanied by
Director General of Developed Pharmacy of Ministry of Health of
the Republic of Indonesia
30 Agustus 2013
Penandatangan Nota Kesepahaman
antara Perseroan dengan PT Deltomed
Laboratories tentang Riset dan Kerja
Sama Kemandirian Bahan Baku Obat, di
Hotel Grand Mercure, Jakarta
The signing of Memorandum of
Understanding between the Company
and PT Deltomed Laboratories
concerning Research and Independence
Cooperation of Medicine Materials, at
Grand Mercure Hotel, Jakarta.
11
1 Oktober 2013
Penandatanganan Kerja Sama antara Perseroan
dengan PT Pelni (Persero) tentang Pelayanan
Kefarmasian Apotek Kimia Farma di RS Pelni,
Pelayanan Kesehatan Karyawan Kimia Farma di RS
Pelni, Pemanfaatan Aset/Bangunan PT Pelni dan
Jasa Pengiriman Barang Kimia Farma di Kantor Pusat
Perseroan, Jakarta
The signing of Cooperation between Company and
PT Pelni (Persero) concerning Pharmacy Service of
Apotek Kimia Farma at Pelni Hospital, Medical Service
of Kimia Farma Employees at Pelni Hospital, the Use
of Assets/Buildings of PT Pelni and Goods Delivery of
Kimia Farma at Head Office of Company, Jakarta
21 Oktober 2013
Perseroan ikut berperan dan mendukung
program Jaminan Kesehatan Nasional di
Sukabumi, Jawa Barat yang dihadiri oleh
Presiden RI dan Para Menteri
September 2013
Oktober 2013
November 2013
Desember 2013
11 Desember 2013
Sosialisasi dan Penandatanganan Pakta Integritas
Manajemen Perseroan dalam mendukung Program
BUMN Bersih di Hotel Aston Marina, Ancol, Jakarta
6 November 2013
Round Table Discussion untuk Penjajakan Potensi L-Lysine
Aescinat dengan Arterium Ukraina di Jakarta
Round Table Discussion for the Survey of Potential L-Lysine
Aescinat with Arterium Ukraina in Jakarta
23 Desember 2013
Penandatanganan
Pengikat Perjanjian Jual
Beli penyertaan saham di
PT Asuransi Jiwa InHealth
Indonesia oleh Perseroan
bersama dengan PT Bank
Mandiri (Persero) Tbk, PT
Askes (Persero) dan PT
Jasindo (Persero) disaksikan
oleh Menteri BUMN RI.
13 November 2013
Kunjungan delegasi dari Asosiasi Industri Toyama Jepang ke
Perseroan untuk Penjajakan Potensi Kerja Sama dan Bisnis.
Delegation visit from the Toyama Industry Association, Japan
to the Company for the Survey of Potential Cooperation and
Business.
12
18 Desember 2013
Grand Launching 100 Apotek dan Klinik Kimia Farma di Tahun
2013 oleh Gubernur Nusa Tenggara Timur, Frans Lebu Raya
di Kupang, Nusa Tenggara Timur.
Grand Launching 100 Drugstore and Clinics of Kimia Farma of
2013 by Governor of East Nusa Tenggara, Frans Lebu Raya
in Kupang, East NusaTenggara.
10
No
11
12
13
14
TANGGAL/
URAIAN PENGHARGAAN
DATE
Descriptions
8 Feb 2013
8 Feb 2013
Produk Salicyl Kimia Farma menerima Top Brand Award 2013 dari
Majalah Marketing & Frontier di Hotel Mulia, Jakarta
Salicyl Kimia Farma Products got Top Brand Award 2013 from
Marketing & Frontier Magazine at Mulia Hotel, Jakarta
26 Feb
2013
27 Feb
2013
24 Apr
2013
7 May 2013
Corporate Secretary Perseroan mendapatkan penghargaan Anugerah Corporate Secretary of the Company got the award of BUMN PR
5 Jun 2013 BUMN Best PR Officer dari Forum Humas BUMN di Hotel Borobudur, Officer from Public Relations HUMAS Forum at Borobudur Hotel,
Jakarta
Jakarta
4 Jul 2013
23 Jul 2013
10
27 Aug
2013
11
30 Aug
2013
12
30 Aug
2013
13
14
The Company through Plant Jakarta and Plant Bandung got the
Proper Award of Blue Ranking from the Ministry of Environment to
Manage the Environment.
Managing Director of PT Kimia Farma Apotek, Imam Fathorrahman
got the Award of Indonesia Marketing Champion 2013 for
Pharmaceutical Sector from MarkPlus, Inc and Indonesia Marketing
Association (IMA) at Ritz Carlton Hotel, Jakarta
13
Kegiatan usaha
manufaktur ini
dikelola oleh
perusahaan
induk yang
memproduksi
obat jadi pharma
dan herbal, bahan
baku Yodium dan
Garam Yodium,
Ferro Sulphate,
Kina & Garam
Kina serta Castor
Oil dan Edible
Oils.
Manufacturing
business activity
is managed by the
holding company,
producing pharma
and herbal medicines,
raw materials Iodine,
Iodine salts, Ferrous
Sulfate, Quinine &
Quinine salts, Castor
Oil, and Edible Oils.
Kegiatan Utama
Main Activities
Manufaktur
Manufacturing
Plant
Jakarta
Bandung
Semarang
Watudakon
Medan
14
No
Lini Produk
ProductS Line
280
item produk
The Company
currently produces
280 products
Jumlah
Quantity
Generik (OGB)
Generics
20
Obat Herbal
Herbal Medicines
10
Kosmetik
Cosmetics
22
Branded Ethical
Branded Ethicals
36
Antiretroviral (ARV)
Antiretroviral (ARV)
Narkotika
Narcotics
13
Kontrasepsi
Contraceptive
Bahan Baku
Raw Materials
14
TOTAL
Perseroan saat
ini memproduksi
sebanyak
154
280
15
Kapasitas Produksi
Kapasitas Produksi
Jenis Sediaan
Unit Research
& Development
melakukan
penelitian
formulasi, baik
untuk sediaan
modern maupun
herbal medicine,
sintesa kimia
sederhana dan
pengembangan
tanaman obat.
The Research &
Development Unit
also conducts
formulation
researches, both for
modern preparation
and herbal medicine,
simple chemical
synthesis and
development of
medical plants.
16
Tablet
a. Betalaktam
b. Non Betalaktam
c. Antiretroviral (ARV)
Tablet Salut
Kapsul
a. Betalaktam
b. Non Betalaktam
c. Antiretroviral (ARV)
Kapsul Lunak
Sirup Kering
a. Betalaktam
b. Non Betalaktam
Salep/Cream
Sirup/Suspensi
InjeksiAmpul
Cairan Obat Luar
Granul
Fitofarmaka
Bedak
Suppositoria
Pil KB
AKDR
Yodium & Garam Yodium
1. Yodium
2. Garam Yodium
3. Garam-Garam Lainnya
Kina & Garam Kina
Minyak Lemak
Dosage Forms
Satuan
Unit
Tablets
a. Betalactam
b. Non Betalactam
c. Antiretrovirals (ARV)
Coated Tablets
Capsules
a. Betalactam
b. Non Betalactam
c. Antiretrovirals (ARV)
Soft Capsules
Dry Syrups
a. Betalactam
b. Non Betalactam
Ointments/Creams
Syrups/Suspensions
InjectionsAmpoules
Liquid Medicines for External Use
Granules
Phytopharmaca
Cosmetics Powders
Suppository
Hormone Contraceptive Pills
IUD
Iodine and Iodine Salts
1. Iodine
2. Iodine Salts
3. Other Salts
Quinine Salts & Other Alkaloid
Edible Oils & Castor Oil
Butir
Butir
Butir
Butir
Butir
Butir
Butir
Butir
Butir
Butir
Kg
Kg
Kg
Kg
Liter
Liter
Liter
Kg
Liter
Kg
Kg
Cycle
Unit
Pcs
Pcs
Pcs
Pcs
Pcs
Pcs
Pcs
Pcs
Pcs
Pcs
Kg
Kg
Kg
Kg
Litre
Litre
Litre
Kg
Litre
Kg
Kg
Cycle
Unit
Kg
Kg
Kg
Kg
Kg
Kg
Kg
Kg
Kg
Kg
Kapasitas/Tahun
Capacity/Year
1.525.430.859
98.917.917
1.365.575.443
60.937.500
432.335.000
249.707.504
50.789.063
158.293.442
40.625.000
74.812.500
45.630
25.830
19.800
141.830
546.048
9.240
229.468
103.800
620.400
691.200
3.469
22.896.000
1.680.000
45.000
34.576
135.675
61.075
3.728.832
Produk Baru
New Products
Produk Etikal
Trombikaf 75 mg Tablet
Codikaf 20 mg Tablet
Kifacain 2 mg Tablet
HaemoctinFactor VIII
Ethical Products
Trombikaf 75 mg Tablet
Codikaf 20 mg Tablet
Kifacain 2 mg Tablet
HaemoctinFactor VIII
Oncology Products
Cisteen 10
Cisteen 50
Epeedo 10
Epeedo 50
Abingem 200
Abingem 1000
Taceedo 20
Taceedo 80
Naprotax 30
Naprodox 10
Naprodox 50
Generic Products
Clopidogrel 75 mg
Glimepiride 1 mg
Glimepiride 2 mg
Glimepiride 3 mg
Glimepiride 4 mg
Produk Herbal
Simplisia Kumis Kucing
Herbal Product
Herbs Orthosiphon sp
Sejalan dengan
perkembangan
teknologi
kedokteran di
bidang terapi,
Perseroan
senantiasa
mengantisipasi
dan menyiapkan
diri untuk
memanfaatkan
peluang yang
ada dengan
merencanakan
pengembangan
bisnis dan produk
ke depan
In line with the
medicine technology
development in
therapy, the Company
always anticipates and
prepares for using any
existing opportunities
by planning the
business and product
development in the
future
17
Perseroan menjadi
pemimpin di
pasar ritel farmasi
dengan jumlah
apotek pada tahun
2013 sebanyak
512
apotek.
The Company is a
market leader for the
pharmaceutical retail
with the number of
drugstore in 2013 in
the number of 512
drugstores.
18
Pemasaran
Marketing
Distribusi
Distribution
Ritel Farmasi
Pharmaceutical Retail
Klinik Kesehatan
Clinics
Laboratorium Klinik
Clinicals Laboratory
Usaha ini
dibangun untuk
melengkapi
portofolio bisnis
Perseroan,
bergerak
dalam bidang
jasa layanan
pemeriksaan
laboratorium rutin,
khusus/rujukan
dan layanan
pemeriksaan
kesehatan
(medical checkup
MCU), baik untuk
karyawan, calon
karyawan dan
masyarakat umum.
This business was
constructed to
complete business
portfolio of the
Company, operating
in the sector of routine
laboratory checkup service, special/
reference and medical
checkupMCU, either
for the employees,
candidate employee
and public.
19
Daerah operasional dari seluruh kegiatan usaha Perseroan tersebar di seluruh Indonesia
Operational Area from all business activities of the Company spread throughout Indonesia
Unit Usaha
Business Unit
Sumatera,
Batam
Jawa
Bali, Nusa
Tenggara
Kalimantan
Sulawesi,
Maluku, Papua
Total
Pabrik/Plant
Distributor/Wholesalers
10
18
44
Apotek/Pharmacies
94
261
44
53
60
512
22
36
Klinik Kesehatan/Clinic
43
94
16
25
22
200
Banda Aceh
Medan
Batam
Pekan Baru
KALIMANTAN
Pontianak
Samarinda
Padang
SUMATERA
Pangkalpinang
Balikpapan
Palangkaraya
Palembang
Bengkulu
Jambi
Banjarmasin
Bandar Lampung
Keterangan/Notes
Tangerang
Pabrik
Plant
Cabang KFTD
KFTD Branch
Unit Bisnis KFA
Business Unit of KFA
20
Jakarta
Cirebon Semarang
Surabaya
JAWA
Bogor
Bandung
Yogyakarta
BALI
Solo
Denpasar
Malang
Jember
Mataram
Manado
Ternate
Sorong
Palu
Jayapura
SULAWESI
Ambon
Kendari
PAPUA
Makassar
Kupang
21
Struktur Organisasi
Organizational Structure
Direktur Utama
President Director
DIREKTUR
Direktur
Operasi &
Supply Chain
Operational &
Supply Chain
Director
Direktur
Umum & Human
Capital
General Affairs
& Human Capital
Director
Direktur
Keuangan
Finance
Director
FUNGSI KORPORASI
General
Manager
Divisi Supply
Chain
Division of
Supply Chain
Divisi
Pengembangan
Bisnis Strategis
Division of
Strategic
Business
Development
Unit Akuntansi
Unit of
Accounting
Manager
Divisi Human
Capital
Division of
Human Capital
Unit Treasuri
Unit of Treasury
Divisi
Sekretaris
Perusahaan
Division of
Corporate
Secretary
Unit Teknologi
Informasi
Unit of
Information
Technology
Divisi Satuan
Pengawas
Intern
Division of
Internal Control
Unit Kepatuhan
& Manajemen
Risiko
Unit of
Compliance
& Risk
Management
OPERATIONAL KORPORASI
General
Manager
SBU
Manufaktur
SBU of
Manufacturing
SBU
Manajemen
Aset
SBU of Asset
Management
SBU Farma
SBU of
Pharmaceutical
SBU Kimia
SBU of
Chemical
Manager
PT KF Trading
& Distribution
PT KF Apotek
Subsidiaries
PT KF
Diagnostika
22
PT Sinkona
Indonesia
Lestari
Keterangan
Description
Holding
Kantor Pusat
SBU Farma
Plant Jakarta
Plant Bandung
Plant Watudakon
Plant Semarang
Plant Medan
Perencanaan & Pengendalian Logistik
Research & Development
Sub Total Holding
PT Kimia Farma Apotek
Kantor Pusat
Cabangcabang
Sub Total KFA
PT Kimia Farma Trading & Distribution
Kantor Pusat
CabangCabang
Sub Total KFTD
PT Sinkona Indonesia Lestari
PT Kimia Farma Diagnostika
Kantor Pusat
CabangCabang
Sub Total KFD
2013
2012
Head Office
SBU Farma
Plant Jakarta
Plant Bandung
Plant Watudakon
Plant Semarang
Plant Medan
Logistic Planning & Control
Research & Development
Sub Total Holding
217
189
301
370
118
79
58
12
71
1.415
209
193
310
393
122
85
63
13
73
1.461
Head Office
Branches
Sub Total KFA
65
2.371
2.436
74
2.461
2.535
Head Office
Branches
Sub Total KFTD
142
859
1.001
143
911
1.054
223
204
22
235
257
5.332
10
196
206
5.460
Head Office
Branches
Sub Total KFD
TOTAL
Tujuan utama
transformasi
SDM adalah
meningkatkan
kompetensi
karyawan,
perbaikan
produktivitas
untuk
meningkatkan
pertumbuhan
bisnis yang
berkelanjutan
serta perubahan
budaya kerja.
The main aims of
transforming Human
Resources are to
improve employees
competency,
the recovery of
productivity to
improve sustainable
business growth and
change of corporate
culture.
1.461
1.415
Holding
2.535
2.436
204
223
206
257
2012
2013
23
Pasca Sarjana
Master Degree
43
Sarjana Lainlain
SD
Other Bachelor Degree
Elementary School
481
275
SLTP
Junior High School
241
Sarjana Akuntansi
Accounting Degree
78
Sarjana
Apoteker
Analis
Pharmacist
Analyst
Degree
162
480
Diploma IV (D-4)
2
Diploma III (D-3)
434
Sarjana Lainlain
Other Bachelor Degree
481
Sarjana Akuntansi
Accounting Degree
79
Analis
Analyst
117
Pasca Sarjana
Master Degree
Diploma II (D-2)
42
5
SD
Diploma I (D-1)
Elementary School
41
305
SLTP
Junior High School
SD
259
305
PENDIDIKAN/
EDUCATION
2013
SAA
School of Assitant
Pharmacy
1.090
Sarjana
Apoteker
Pharmacist
Degree
426
Diploma IV (D-4)
2
Diploma III (D-3)
407
Diploma II (D-2)
6
Diploma I (D-1)
41
PENDIDIKAN/
EDUCATION
2012
SLTA
Senior
High
School
2.101
SAA
School of Assitant
Pharmacy
1.194
Pendidikan
Education
Jumlah
2013
2012
Persentase
Jumlah
Total
Percentage
Total
Percentage
Persentase
SD
Elementary School
275
5,16%
305
5,59%
SLTP
241
4,52%
259
4,74%
SLTA
2.000
37,51%
2.101
38,48%
SAA
1.090
20,44%
1.194
21,87%
Diploma I (D-1)
Diploma I (D-1)
41
0,77%
41
0,75%
Diploma II (D-2)
Diploma II (D-2)
0,09%
0,11%
434
8,14%
407
7,45%
Diploma IV (D-4)
Diploma IV (D-4)
0,04%
0,04%
Analis
Analyst
162
3,04%
117
2,14%
Sarjana Akuntansi
Accounting Degree
78
1,46%
79
1,45%
Sarjana Apoteker
Pharmacist Degree
480
9,00%
426
7,80%
Sarjana Lainlain
481
9,02%
481
8,81%
Pasca Sarjana
Master Degree
43
0,81%
42
0,77%
5.332
100%
5.460
100%
TOTAL
24
SLTA
Senior
High
School
2.000
2025
368
5155
931
Berdasarkan Usia
Tahun 2012 dan 2013
Based on AGE of 2012
and 2013
2630
659
5155
712
2025
430
2630
790
2012
4145
883
2013
4145
815
USIA/
AGE
4650
1.130
USIA/
AGE
4650
1.031
3640
740
3135
762
Usia/Age
3640
753
3135
788
Jumlah
2013
2012
Persentase
Jumlah
Total
Percentage
Total
Percentage
2025
368
6,90%
430
7,88%
2630
659
12,36%
790
14,47%
3135
788
14,78%
762
13,96%
3640
740
13,88%
753
13,79%
4145
815
15,29%
883
16,17%
4650
1.031
19,34%
1.130
20,70%
931
17,46%
712
13,04%
5.332
100%
5.460
100%
5155
TOTAL
General
Manager
9
Manager
56
Asistant Manager
426
Persentase
PTT
909
Manager
56
Asistant Manager
319
Supervisor
626
JABATAN/
POSITION
2013
PTT
929
Supervisor
725
Pelaksana
3.306
JABATAN/
POSITION
2012
Pelaksana
3.431
Jabatan/
Position
Jumlah
2013
2012
Persentase
Jumlah
Total
Percentage
Total
Percentage
General Manager
0,17%
Manager
56
1,05%
56
1,03%
Asistant Manager
426
7,99%
319
5,84%
Supervisor
626
11,74%
725
13,28%
Pelaksana
3.306
62,00%
3.431
62,84%
909
17,05%
929
17,01%
5.332
100%
5.460
100%
PTT
TOTAL
Persentase
25
26
Komisaris Independen/
Independent Commissioner
27
28
29
Profil Direksi
Profile of The Board of Directors
Arief Budiman
Direktur Keuangan/
Finance Director
30
M. Wahyuli Syafari
Direktur Riset
& Pengembangan Bisnis/
Research & Business
Development Director
Rusdi Rosman
Direktur Utama/
President Director
Pujianto
Direktur Umum
& Human Capital/
General Affair
& Human Capital Director
Jisman Siagian
31
Profil Direksi
Profile of The Board of Directors
Rusdi Rosman
Arief Budiman
32
Jisman Siagian
M. Wahyuli Syafari
Pujianto
Direktur Umum & Human Capital/General Affair & Human Capital Director
Menyelesaikan pendidikan Apoteker dari Universitas
Gadjah Mada Yogyakarta dan melanjutkan studi S2
di UHAMKA Jakarta program Magister Manajemen.
Pernah menjabat sebagai Manajer Bisnis Apotek
Wilayah DKI Jaya 2 tahun 20092011, Manager
Binabang SDM Perseroan tahun 20112012 dan
jabatan terakhir sebelum diangkat menjadi Direktur
Umum & Human Capital pada tahun 2012 adalah
General Manager Human Capital Perseroan.
33
Profil Saham
Profile of Shares
Saham Perseroan
diperdagangkan
di Bursa Efek
Indonesia dengan
simbol saham
KAEF
The Company
shares are traded
at Indonesia Stock
Exchange under a
share symbol of KAEF.
Pemegang Saham
Pemerintah RI
Saham Seri A Dwiwarna
Saham Seri B Biasa
Perorangan/Umum
Saham Seri B Biasa
Manajemen & Karyawan
Manajemen
- Jisman Siagian
- Pujianto
Karyawan
Saham Seri B Biasa
TOTAL
Shareholders
Government of RI
Dwiwarna Series A Shares
Ordinary Series B Shares
Individual/Public
Ordinary Series B Shares
Management & Employee
Management
- Jisman Siagian
- Pujianto
Employees
Ordinary Series B Shares
Jumlah
Saham
Jumlah
Jumlah
Kepemilikan
Number of
Share
Total
Percent of
Ownership
1
4.999.999.999
100
499.999.999.900
0,000%
90,025%
544.805.000
9.195.000
54.480.500.000
919.500.000
9,809%
0,166%
82.500
42.500
9.070.000
8.250.000
4.250.000
907.000.000
5.554.000.000
555.400.000.000
100,000%
Pembagian Dividen
Distribution of Dividends
Pembagian dividen selama lima tahun terakhir seperti tertera pada tabel berikut ini:
The distribution of dividends in the last five years is as shown in the following table:
34
Tahun
Year
Allocation of Government
Take Dividends (Rupiah)
Total Dividends
(Rupiah)
2008
12.467.090.131
1.381.353.586
13.848.443.717
2009
16.881.500.000
1.870.562.953
18.752.062.953
2010
24.975.881.185
2.767.327.635
27.743.208.820
2011
30.926.447.148
3.426.750.344
34.353.197.492
2012
27.700.753.957
3.069.243.538
30.769.997.495
PT Datindo Entrycom
Puri DatindoWisma Sudirman
Jl. Jend. Sudirman Kav 3435
Jakarta 10220
2. Kantor Akuntan Publik
Dalam Rapat Umum Pemegang Saham Tahunan
Perseroan yang dilaksanakan pada tanggal 10
April 2013 telah memutuskan menunjuk Kantor
Akuntan (KAP) Publik Hendrawinata Eddy &
Siddharta (afiliasi dari Kreston International)
register Public Accountant License Number
1212/KM.1/2011 untuk mengaudit Laporan
Keuangan Konsolidasian dan Laporan Auditor
Independen Perseroan dan anak perusahaan dan
pengelolaan pelaksanaan Program Kemitraan
dan Bina Lingkungan untuk tahun yang berakhir
31 Desember 2013. Fee untuk jasa audit Tahun
Buku 2013 sebesar Rp645.000.000,00. Partner
yang memeriksa adalah Iskariman Supardjo ijin
Akuntan Publik Nomor AP.0336.
Kantor Akuntan Publik (KAP) Hendrawinata
Eddy & Siddharta
(Kreston International)
Intiland Tower Lantai 8
Jl. Sudirman Kav.32
Jakarta 10220
PT Datindo Entrycom
Puri DatindoWisma Sudirman
Jl. Jend. Sudirman Kav 3435
Jakarta 10220
2. Public Accountant Office
In the Annual General Meeting of Shareholders
held on April 10, 2013 resolved to appoint Public
Accountant Office (PAO) of Hendrawinata Eddy
& Siddharta (affiliation from Kreston International)
register of Public Accountant License Number
1212/KM.1/2011 to audit Consolidated Financial
Statement and Independent Auditor Statement of
the Company and subsidiary and management
of operating Partnership and Developed
Environment Program ended on December 31,
2013. Fee for audit service of 2013 Fiscal Year
in the amount of Rp645,000,000.00. Partner
auditing is Iskariman Supardjo Public Accountant
license Number AP.0336.
3. Securities Company
The Company has nominated PT Pemeringkat
Efek Indonesia (PT Pefindo) to make evaluation
and rating of Company in 2013 with the result of
(AA-).
35
Profil Perseroan
Company Profile
Teknologi yang
saat ini sedang
dikembangkan
oleh Perseroan
adalah teknologi
informasi berbasis
Enterprise
Resources
Planning (ERP)
untuk melakukan
transaksi sehingga
diperoleh catatan
lengkap dan
dapat digunakan
untuk melakukan
pengikhtisaran
dengan baik.
The technology
which is currently
being developed
by the Company
is information
technology based on
Enterprise Resources
Planning (ERP) to
run transaction so
obtained complete
record and can be
used to highlight very
well.
36
41
Tinjauan Manajemen 46
Management Review
Tinjauan Kegiatan Usaha 49
Business Review
Tinjauan Kegiatan Usaha Pendukung 54
Review of Supporting Business Activities
Tinjauan Keuangan 59
Financial Review
Peluang & Strategi Perseroan Tahun 2014 65
Opportunity and Strategy of Company in 2014
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
37
38
Dear Shareholders,
Walaupun
perekonomian
nasional tidak
begitu kondusif,
kinerja Perseroan
pada tahun 2013
masih tetap
mengalami
peningkatan dari
tahun 2012.
Even though
national economy
is not so conducive,
performance of the
Company in 2013
remained improving
since 2012.
39
5 Maret 2014
5 March 2014
Dewan Komisaris
Board of Commissioners
40
Laporan Direksi
Report of Board of Directors
Rusdi Rosman
Direktur Utama/
President Director
41
Laporan Direksi
Report of Board of Directors
Dear Shareholder,
Manajemen
Perseroan
menyadari bahwa
Perseroan untuk
dapat terus
berkembang,
agar mampu
memberikan nilai
tambah yang
berkelanjutan,
perlu didukung
budaya inovatif
yaitu dengan
membentuk pola
pikir seluruh
jajaran Perseroan
untuk berpikir
out of the box,
smart dan kreatif
guna membangun
bisnis unggulan.
Dear shareholder,
The Management
realizes that the
Company to keep
growing, and to
be able to give
sustainable added
value, it is necessary
to support innovative
culture namely by
making mindset of all
lines of the Company
to think out of the box,
smart and creative
to build excellent
business.
42
Terkait dengan
besarnya
ketergantungan
bahan baku
obat yang harus
impor dari luar
negeri, Perseroan
ke depan
menginisiasi
untuk bisa
mewujudkan
kemandirian
bahan baku obat
dalam negeri.
Due to dependency
on the raw materials
of the medicine that
must be imported
from the foreign
country, the Company
initialize to materialize
its independency
for the domestic raw
materials of medicine
in years to come
43
Laporan Direksi
Report of Board of Directors
Perseroan
percaya bahwa
pertumbuhan
kinerja yang
dicapai sampai
dengan saat ini,
memiliki kaitan
yang erat dengan
penerapan prinsipprinsip Tata
Kelola Perusahaan
yang Baik yang
dilaksanakan
secara konsisten
oleh seluruh
jajaran Perseroan.
The Company
trusts that the
present performance
development, is
interconnected with
the application of
principles for the
Good Corporate
Governance
conducted
consistently by all
lines of the Company.
44
Dear shareholder,
5 Maret 2014
5 March 2014
Direksi
Board of Directors
Rusdi Rosman
Direktur Utama
President Director
Arief Budiman
Direktur Keuangan
Finance Director
Jisman Siagian
Direktur Operasi & Supply
Chain
Operation & Supply Chain
Director
M. Wahyuli Syafari
Direktur Riset &
Pengembangan Bisnis
Research & Business
Development Director
Pujianto
Direktur Umum & Human
Capital
General Affair & Human Capital
Director
45
Tinjauan Manajemen
Management Review
Pertumbuhan
ekonomi
Indonesia
tahun 2013
tercatat sebesar
5,78%
mengalami
pelambatan
dibandingkan
dengan tahun 2012
yang mencapai
6,11%
In 2013 Indonesia
economy growth was
listed by 5.78% down
compared to 2012 to
the reach of 6.11%
46
2012
5.78
6.11
8.38
4.30
11,900
9,670
7.50
5.75
6.2
Pertumbuhan
PDB Indonesia/
Indonesian GDP
Growth
5.8
4.6
35
17.5
6.5
6.2
6.0
11.1
7.0
2.8
2008
2009
3.8
2010
8.4
4.3
2011
2012
2013
Tingkat Inflasi
Indonesia/
Indonesian
Inflation Rate
Rupiah mengalami
depresasi cukup
signifikan selama
tahun 2013.
Rupiah expressed
significant depression
during the year of
2013.
4.8%
4.1%
3.8%
3.5%
3.3%
2.1%
1
0
Malaysia
Thailand
Philippines
India
Singapore
Indonesia
47
Tinjauan Manajemen
Management Review
4Q 12 MAT
+%
Total Market
market desc
53.809
47.650
12,93
Panel Market
22.430
19.919
12,61
6.288
5.249
19,79
7.484
6.278
19,21
8.659
8.392
3,18
Non-Panel Market
31.379
27.731
13,15
14.243
12.875
10,63
17.135
14.856
15,35
Di sektor
industri farmasi,
perusahaan
farmasi masih
sangat tergantung
kepada transaksi
impor untuk
memenuhi
kebutuhan bahan
bakunya. Impor
bahan baku
mencapai 90%
dari total
kebutuhan bahan
baku industri.
In the sector of
pharmaceutical
industry,
pharmaceutical
company is still
dependent on the
import transaction
to meet the raw
materials. Import of
raw materials reached
90% of total need
of the industry raw
materials.
48
Segment Review
Manufaktur
Manufacturing
Satuan
Kapasitas/Tahun
Realisasi 2013
Realisasi 2012
Dosage Forms
Unit
Capacity/Year
Realization 2013
Realization 2012
Tablet
a. Betalaktam
b. Non Betalaktam
c. Antiretroviral (ARV)
Tablet Salut
Kapsul
a. Betalaktam
b. Non Betalaktam
c. Antiretroviral (ARV)
Kapsul Lunak
Sirup Kering
a. Betalaktam
b. Non Betalaktam
Salep/Cream
Sirup/Suspensi
InjeksiAmpul
Cairan Obat Luar
Granul
Fitofarmaka
Bedak
Suppositoria
Pil KB
AKDR
Yodium & Garam Yodium
a. Yodium
b. Garam Yodium
c. Garam-Garam Lainnya
Kina & Garam Kina
Minyak Lemak
Butir/Pcs
Butir/Pcs
Butir/Pcs
Butir/Pcs
Butir/Pcs
Butir/Pcs
Butir/Pcs
Butir/Pcs
Butir/Pcs
Butir/Pcs
Kg
Kg
Kg
Kg
Liter/Litre
Liter/Litre
Liter/Litre
Kg
Liter/Litre
Kg
Kg
Cycle
Unit
Kg
Kg
Kg
Kg
Kg
1.525.430.859
98.917.917
1.365.575.443
60.937.500
432.335.000
249.707.504
50.789.063
158.293.442
40.625.000
74.812.500
45.630
25.830
19.800
141.830
546.048
9.240
229.468
103.800
620.400
691.200
3.469
22.896.000
1.680.000
1.476.195.686
231.901.900
1.197.784.156
46.509.630
262.445.652
62.303.280
4.893.720
54.900.040
344.160
25.668.000
20.692
2.784
17.660
176.778
248.452
8.832
223.484
39.140
520.548
753.200
1.865
7.973.900
19.815
1.983.988.572
172.219.400
1.786.037.932
25.731.240
549.542.608
75.753.550
7.968.480
65.448.320
48.368.000
17.984
10.996
6.598
189.499
270.012
13.494
191.799
70.595
465.901
551.888
3.385
5.181.500
31.184
45.000
34.576
135.675
61.075
3.728.832
43.150
11.184
21.392
41.504
1.324.648
44.150
10.232
19.640
61.366
2.655.412
Perseroan telah
melakukan
beberapa
peningkatan
fasilitas produksi
pada tahun 2013,
seperti upaya
peningkatan
efektivitas dan
efisiensi dari 5
pabrik untuk
memperoleh hasil
yang maksimal.
The Company
has made some
improvement of
the production
facilities in 2013, as
efforts to increase
the effectiveness
and efficiency of the
5 plants to obtain
maximum results.
49
Pengaturan
produk-produk
yang diproduksi
pada tiap pabrik
diatur ulang
yang mengarah
pada optimalisasi
penggunaan
mesin-mesin
sehingga dapat
dicapai utilisasi
yang optimal,
dengan sasaran
tepat mutu, tepat
jumlah, tepat
waktu, dan tepat
biaya.
The production
planning at each
factory is intended
to optimize the use
of the machines in
order to achieve the
goals: better quality,
proper amount, on
time delivery, and cost
effectiveness.
50
Distribusi
Distribution
Selama ini,
KFTD mampu
menjalankan
Cara Distribusi
Obat yang Baik
(CDOB), karena
adanya kerja
tim yang baik
antara seluruh
bagian, partisipasi
seluruh karyawan,
dan juga fungsi
pengawasan yang
baik.
Up to now, KFTD
has been capable of
implementing Good
Distribution Practice
(GDP) due to good
team work among all
divisions, participation
of all employees and
also good control
function.
51
52
B
C
D
E
F
G
Uraian
Description
Apotek
KFA
Apotek Swasta
Pharmacy
KFA
Private Pharmacy
Toko Obat
Rumah Sakit
Pasar Modern
Grosir
KFTD Sub Distribusi
Lainlain
Drugstore
Hospital
Modern Market
Wholesaler
KFTD Sub Distribution
Others
TOTAL
512
13.693
14.123
2.794
1.803
1.890
550
724
68
Ritel Farmasi
Pharmaceutical Retail
Pengembangan Usaha
Business Development
Klinik Kesehatan
Clinic
Laboratorium Klinik
Clinical Laboratory
200
klinik pratama
dan utama
yang tersebar di
seluruh Indonesia.
Pengembangan
produk layanan
berupa klinik
kesehatan
ini sejalan
dengan rencana
pelaksanaan
program Jaminan
Kesehatan
Nasional (JKN)
Pemerintah.
In 2013, there have
been 200 the first and
main clinics spread
throughout Indonesia.
The development of
service products in
terms of this clinic
in line with the
plan of operating
Government National
Health Security.
53
Perseroan telah
melakukan
beberapa
pengembangan
bisnis dan produk
baru di tahun 2013
untuk mendukung
peningkatan
kinerja Perseroan
The Companys has
been doing some new
product and business
development in
2012 to support the
improved performance
of the Company
54
Perseroan
telah
melakukan
beberapa
pengembangan bisnis dan produk baru di tahun
2013 untuk mendukung peningkatan kinerja
Perseroan yaitu:
Pengembangan Bioteknologi
Development of Biotechnology
a. Skin Culture
Digunakan untuk pengobatan luka bakar
b. Stem Cell
Digunakan
untuk
pengobatan
dengan
pemanfaatan sel punca, termasuk pelayanan
bank cell
a. Skin Culture
Used for the treatment of burns
b. Stem Cell
Used to treatment by utilizing stem cells, including
cells bank services cells
Pengembangan Radiofarmasi
Development of Radiopharmaceutical
Construction of Hospital
Pemasaran
Marketing
Kegiatan R&D
dilakukan dengan
cara mandiri,
bekerja sama
dengan perguruan
tinggi dan
lembaga riset serta
under licenses
scheme
The activities of the
R&D are carried out by
means of independent,
cooperating with
universities and other
research institutions
as well as under
licences scheme.
55
Produk-produk
yang dipasarkan
oleh Perseroan
terdiri dari produk
Generik, Etikal,
OTC, Kosmetik,
Narkotika dan
obat-obat khusus
untuk menunjang
program
Pemerintah.
The products
marketed by the
Company consist of
Generic, Ethical, OTC,
Cosmetics, Narcotics
and specialty
medicines to support
the Government
Program.
56
Human Resource
1. Human
Resource
Development
Management
Secara
keseluruhan,
program
pengembangan
SDM tahun 2013
menjabarkan
program yang
sudah disusun
dalam Rencana
Jangka Panjang
Perusahaan
As a whole, Human
Resource development
of 2013 described
the program already
prepared in the LongTerm Plan (LTP) of the
Company
57
Pengembangan
kompetensi SDM
yang diawali
dengan penetapan
Competency
Level Index
(CLI) kemudian
pengembangan
SDM dilakukan
berdasar
kompetensi dan
job requirement
serta diharapkan
akan tercipta SDM
yang berkualitas &
profesional sesuai
dengan strategi
bisnis Perseroan.
Human Resource
competency
development
initialized by
stipulating
Competency Level
Index (CLI), Human
Resource development
is made based on
the competency and
job requirement and
hopefully the qualified
and professional
Human Resource
will be created in
accordance with the
business strategy of
the Company.
58
2. Human
Resource
Development
Competency
Tinjauan Keuangan
Financial Review
Penjualan Bersih
Net Sales
Description
2013
Local Sales
Third Party
Related Partes
Export Income
Quinine Salt
Iodine & Derivatives
Drugs & Medical Devices
TOTAL
Pertumbuhan
2012
4.145.116
3.837.162
307.954
202.958
106.774
21.963
74.221
4.348.074
Growth
3.589.046
3.292.701
296.345
145.195
103.448
27.389
14.358
3.734.241
15,49%
16,54%
3,92%
39,78%
3,22%
(19,81%)
416,97%
16,44%
Penjualan Bersih
Perseroan
mencapai
Rp4,35 triliun
atau meningkat
16,44%
dibanding tahun
2012.
Laba Rugi Konsolidasi Tahun 2012 dan 2013 (Dalam Juta Rupiah)
Consolidated Income Statement of 2012 and 2013 (In Million Rupiah)
Uraian
Description
Penjualan Bersih
Beban Pokok Penjualan
Laba Bruto
Beban Usaha
Administrasi Umum
Penjualan
Laba Usaha
Penghasilan (Beban) Lain
Laba Sebelum Pajak
Beban Pajak
Laba Bersih
Net Sales
Cost of Good Sold
Gross Profit
Operating Expenses
General Administration
Sales
Operating Profit
Other Income (Expenses)
Income Before Tax
Tax Expenses
Net Profit
2013
4.348.074
3.055.922
1.292.152
1.042.619
425.790
616.829
249.533
44.232
284.125
68.483
214.549
2012
3.734.241
2.559.074
1.175.167
912.599
373.113
539.486
262.568
22.589
278.284
72.520
205.133
Selisih
Pertumbuhan
Increment
Growth
613.833
496.848
116.985
130.020
52.677
77.343
(13.035)
21.643
5.841
(4.037)
9.416
16,44%
19,42%
9,95%
14,25%
14,12%
14,34%
(4,96%)
95,81%
2,10%
(5,57%)
4,59%
59
Tinjauan Keuangan
Financial Review
Laba bersih
yang dapat
diatribusikan
kepada pemilik
entitas induk
pada tahun 2013
meningkat sebesar
4,59%
menjadi Rp214,55
miliar apabila
dibandingkan
dengan laba bersih
tahun 2012 yang
sebesar Rp205,13
miliar.
Net profit that may
be distributed to the
owner of Holding
entity of 2013
increased 4.59% to
Rp214.55 billion if
compared to the
2012 net profit in the
amount of Rp205.13
billion.
60
Laba Bruto
Laba Bruto
Beban Usaha
Operating Expense
Laba Usaha
Operating Profit
Laba Bersih
Net Profit
Total Aset
Total Assets
Aset Lancar
Current Assets
Description
2013
2012
316.498
199.386
Selisih
Pertumbuhan
Increment
Growth
117.112
253.784
230.613
23.171
10,05%
(172.809)
(65.118)
(107.691)
165,38%
(3.322)
(48.382)
45.060
(93,13%)
77.653
117.112
(39.461)
(33,69%)
394.150
316.498
77.652
24,53%
Piutang Usaha
Trade Receivables
Persediaan
Inventory
Non-Current Assets
58,74%
24,53%
dari tahun 2012
yang sebesar
Rp316,49 miliar.
Kenaikan ini
merupakan
dampak dari
kenaikan
penjualan
Perseroan.
61
Tinjauan Keuangan
Financial Review
Posisi Keuangan Konsolidasi Tahun 2012 dan 2013 (Dalam Juta Rupiah)
Consolidated Balance Sheet 2012 and 2013 (In Million Rupiah)
Uraian
Aset Lancar
Aset Tidak Lancar
Jumlah Aset
Liabilitas Jangka Pendek
Liabilitas Jangka Panjang
Jumlah Liabilitas
Ekuitas
Jumlah Liabilitas & Ekuitas
12,74%
menjadi Rp1,61
triliun.
62
Description
Current Asset
Non-Current Asset
Total Asset
Current Liabilities
Non-Current Liabilities
Total Liabilities
Equity
Total Equity & Liabilities
2013
1.810.615
661.325
2.471.940
746.123
101.462
847.585
1.608.225
2.471.940
2012
1.505.798
570.549
2.076.348
537.184
97.630
634.814
1.426.497
2.076.348
Selisih
Pertumbuhan
Increment
Growth
304.817
90.776
395.592
208.939
3.832
212.771
181.728
395.592
20,24%
15,91%
19,05%
38,90%
3,93%
33,52%
12,74%
19,05%
Liabilitas
Liability
Short-Term Liabilities
Long-Term Liabilities
Ekuitas
Equity
Investasi
Investment
Kebijakan
pembagian
dividen
merupakan
kewenangan sepenuhnya dari Rapat Umum
Pemegang Saham (RUPS). Dividend payout ratio
Tahun Buku 2008, sebesar 25%. Untuk Tahun Buku
2009, pembagian dividen sebesar 30%. Tahun
Buku 2010, pembagian dividen sebesar 20%.
Untuk dividen Tahun Buku 2011, pembagian dividen
sebesar 20%, sedangkan untuk Tahun Buku 2012,
pembagian dividen sebesar 15% dan untuk Tahun
Buku 2013 menunggu pelaksanaan RUPS Tahun
Buku 2013.
Sepanjang tahun
2013, Perseroan
melaksanakan
investasi aset tetap
sebesar Rp199,27
miliar. Investasi
aset tetap tahun
2013 lebih tinggi
sebesar Rp117,47
miliar, atau naik
143,60%
dibandingkan
tahun 2012.
63
Tinjauan Keuangan
Financial Review
64
Perekonomian
Indonesia yang
terus bertumbuh,
peningkatan
daya beli dan
tingkat kesadaran
masyarakat
terhadap
kesehatan yang
meningkat,
memberikan
peluang bagi
industri untuk
dapat terus
meningkatkan
pangsa pasarnya,
perusahaan
akan terus
berinovasi untuk
meluncurkan
produk-produk
baru.
Indonesian economy
which keeps growing,
improvement of
purchase power and
public awareness
level towards better
recovery, giving
opportunity for the
industry to keep
improving the market
share, the company
will keep innovating
to launch the new
products.
65
Pengembangan
Bisnis Perseroan
ke depan sesuai
dengan program
Transformasi
Perseroan dan
Road Map to
be Healthcare
Company,
Perseroan
melakukan
investasi pada
beberapa sektor
bisnis baik core
business maupun
non core business
khususnya pada
sektor core
business yang
bersinggungan
secara langsung
dengan potensi
pasar.
Business development
of the Company
in years to come
conforms to the
Transformation
program of the
Company and Road
Map to be Healthcare
Company, the
Company invests in
some business sectors
either core business
or non core business
especially in the
sector of core business
directly relating to the
potential market.
66
67
Keseriusan
Perseroan
diwujudkan
dalam komitmen
Perseroan untuk
menerapkan
prinsip-prinsip
Tata Kelola
Perusahaan
yang Baik (Good
Corporate
Governance/GCG)
secara terstruktur
dan bertahap
sesuai dengan
pelaksanaan
Rencana Jangka
Panjang Perseroan
(RJPP).
The seriousness
of Company was
materialized in the
commitment of the
Company to apply
the principles of
Good Corporate
Governance/GCG by
structure and in stages
in accordance with
the Implementation of
Long-Term Plan of the
Company.
68
1. Keterbukaan Informasi
Perseroan
bersifat
terbuka
dalam
melaksanakan proses pengambilan keputusan
dan
mengutamakan
keterbukaan
dalam
mengungkapkan informasi material dan relevan
mengenai Perseroan. Dalam proses pengambilan
keputusan, manajemen Perseroan terikat
pada mekanisme sebagaimana diatur dalam
Panduan Dewan (Board Manual) dan dalam
mengungkapkan informasi material Perseroan
disampaikan melalui Corporate Secretary.
1. Disclosure of Information
The Company is open to process decisionmaking and prioritize transparency to disclose
information on materials and relevant to the
Company. In the process of decision-making,
management of the Company relating to the
mechanism as provided in Board Manual and to
disclose information on materials of the Company
delivered through Corporate Secretary.
2. Akuntabilitas
Dalam menjalankan kegiatan, Perseroan memiliki
sistem pengelolaan Perseroan yang mendukung
terciptanya kejelasan fungsi, pelaksanaan dan
pertanggungjawaban organ Perseroan sehingga
pengelolaan Perseroan terlaksana secara
efektif. Langkahlangkah yang dilakukan untuk
menegakkan prinsip akuntabilitas antara lain
Pelaporan Direksi kepada Dewan Komisaris
mengenai RKAP Tahunan, penyampaian Laporan
Keuangan pada Rapat Umum Pemegang
Saham (RUPS) Tahunan, pembentukan Audit
Internal dan penunjukkan Auditor Eksternal
serta pemberlakuan Pedoman Standar Perilaku
(Code of Conduct/CoC), Pedoman Benturan
Kepentingan serta Pedoman Penerimaan
Gratifikasi.
2. Accountability
In carrying out the activity, the Company
has management system of the Company in
support of the creation of clarity for the function,
implementation and accountability of the
Company so that the management of Company
is effectively carried out. Steps made to uphold
accountability principle such as Reporting of
Board of Directors to the Board of Commissioners
concerning Annual APB, submission of Annual
General Meeting of Shareholders, establishment
of Internal Audit and nomination of External
Auditor and enforcement of Code of Conduct
(CoC), Guidelines on Conflict of Interest and
Receipt of Gratification.
3. Pertanggungjawaban
Dalam
menjalankan
kegiatan,
Perseroan
memiliki Sistem Pengelolaan Perseroan yang
menitikberatkan pada kejelasan tugas dan
tanggung jawab setiap personel, sehingga
insan Perseroan dapat melaksanakan tanggung
jawabnya dengan efektif. Langkahlangkah
yang dilakukan untuk menegakkan prinsip
responsibilitas antara lain pembuatan Laporan
Pajak-Pajak Pribadi (LP2P), Laporan Penerimaan
Gratifikasi dan Laporan Benturan Kepentingan.
Setiap pekerja juga diwajibkan untuk patuh dan
taat terhadap aturan internal maupun aturan
perundang-undangan.
3. Responsibility
In carrying out the activities, the Company has
Company Management System placing emphasis
on the clarity of tasks and responsibilities of any
personnel, so that the officer of the Company can
carry out his/her responsibility effectively. Steps
taken are to uphold principle of responsibility
among other things the making of Individual
Tax Report (LP2P), Reports on the Receipt of
Gratification and Conflict of Interest. Each worker
is also obliged to abide by and observe towards
internal laws and regulation.
4. Kemandirian
Perseroan memastikan bahwa pengelolaan
Perseroan dilaksanakan secara independen tanpa
adanya benturan kepentingan dan pengaruh atau
tekanan dari pihak manapun yang tidak sesuai
dengan peraturan perundang-undangan dan
prinsip korporasi yang sehat.
4. Independence
The Company ensured that the management is
independently conducted without any conflict
of interest and effect or pressure from any
party which does not comply with the laws and
regulation and the principle of fair corporate.
Good
Corporate
Tema
Operational
Excellence
tercermin di
dalam komitmen
dan konsistensi
Perseroan
untuk selalu
meningkatkan
kualitas penerapan
Tata Kelola
Perusahaan yang
Baik, dengan
semangat yang
selalu baru
serta dengan
menciptakan
ruang untuk
inovasi dan
kreativitas.
The theme of
Operational
Excellence is reflected
in the commitment
and consistency
of the Company to
always improve the
quality of applying
Good Corporate
Governance, with the
new spirit and creating
room for innovation
and creativity.
69
I
II
III
IV
V
VI
I
II
III
IV
V
VI
Aspek Pengujian/Indikator/
Parameter
EXAMINATION ASPECTS/INDICATOR/
PARAMETERS
Aspek Pengujian/Indikator/
Parameter
EXAMINATION ASPECTS/INDICATOR/
PARAMETERS
Kemampuan yang tinggi dalam menerapkan prinsipprinsip GCG telah diwujudkan oleh Perseroan
diantaranya dengan dibentuknya fungsi pengelolaan
GCG di bawah Unit Kepatuhan dan Manajemen
Risiko yang secara khusus menangani dan
memantau efektivitas penerapan GCG di Perseroan.
Perseroan secara berkesinambungan melakukan
langkah-langkah perbaikan baik dari sisi soft
structure maupun dari sisi infrastruktur GCG dalam
rangka meningkatkan kualitas penerapan GCG.
70
Capaian
Tahun 2012/
Bobot/ ACHIEVEMENT
IN 2012
RANK
Skor/
%
SCORE
Penjelasan/
DESCRIPTION
7,000
4,268
60,97
9,000
35,000
35,000
9,000
0,000
7,674
27,947
21,485
5,882
0,000
67,256
85,27
79,85
61,39
65,36
Capaian
Tahun 2013/
Bobot/ ACHIEVEMENT
IN 2013
RANK
Skor/
%
SCORE
Penjelasan/
DESCRIPTION
7,000
5,878
83,96
Baik/Good
9,000
35,000
35,000
9,000
0,000
7,674
29,772
27,846
7,137
0,000
78,306
85,26
85,06
79,56
79,30
Dewan Komisaris
Board of Commissioners
Dalam
melaksanakan
tugasnya, Dewan
Komisaris harus
mematuhi
Anggaran Dasar
Perseroan dan
Ketentuan
peraturan
perundangundangan yang
berlaku serta wajib
melaksanakan
prinsip-prinsip
profesionalisme,
efisiensi,
transparansi,
kemandirian,
akuntabilitas,
pertanggungjawaban serta
kewajaran.
In carrying out its
duties, the Board
of Commissioners
shall comply with the
Articles of Association
of the Company and
the provisions of
laws and regulations
as well as carry out
mandatory principles
of professionalism,
efficiency,
transparency,
independence,
accountability,
responsibility and
fairness.
71
RUPS merupakan
Organ Perseroan
yang mempunyai
wewenang yang
tidak diberikan
kepada Direksi
atau Dewan
Komisaris
dalam batas
yang ditentukan
dalam UndangUndang Nomor
40 Tahun 2007
tentang Perseroan
Terbatas dan/atau
Anggaran Dasar
Perseroan.
General Meeting of
Shareholders is Organ
of the Company
having authority
which is not granted
to the Board of
Directors or Board of
Commissioners in the
limited as provided
in Law Number 40
of 2007 concerning
Limited Liability
Company and/or
Companys Articles of
Association.
72
Nama
Name
1
2
3
4
5
Ratna Rosita
Upik Rosalina Wasrin
Wahono Sumaryono
Effendi Rangkuti
Darmansyah
1
2
3
4
5
Supriyantoro
Dewi Fortuna Anwar
Wahono Sumaryono
Farid Wadjdi Husain
Basuki Ranto
Jabatan
Title
Kehadiran
Attendance
6/6
3/6
6/6
6/6
6/6
8/11
8/11
10/11
8/11
11/11
Catatan: Dalam rangka pelaksanaan GCG, Komisaris yang berhalangan hadir dalam rapat karena melaksanakan tugas penting lain yang bersamaan waktunya
diwakili oleh Komisaris lainnya yang mendapat pelimpahan wewenang tugas serta memiliki suara yang sah.
Notes: In the implementation of GCG, the Board of Commissioners who is absent due to other important tasks, then at the same time, it may be represented by
other Board of Commissioners who has been authorized the delegation of duty and has valid voting.
Rapat Dewan Komisaris dapat diadakan sekurangkurangnya setiap bulan sekali atau setiap waktu
bilamana dianggap perlu oleh Komisaris Utama
atau oleh 1/3 dari jumlah anggota Dewan Komisaris
atau atas permintaan tertulis dari Rapat Direksi
atau atas permintaan sedikitnya 1/10 bagian dari
seluruh jumlah saham dengan hak suara yang sah.
Sepanjang tahun 2013, Dewan Komisaris telah
melaksanakan Rapat Dewan Komisaris sebanyak
17 kali.
Rapat Dewan
Komisaris
dapat diadakan
sekurangkurangnya
setiap bulan
sekali atau setiap
waktu bilamana
dianggap perlu
oleh Komisaris
Utama atau oleh
1/3 dari jumlah
anggota Dewan
Komisaris atau
atas permintaan
tertulis dari Rapat
Direksi atau
atas permintaan
sedikitnya 1/10
bagian dari
seluruh jumlah
saham dengan hak
suara yang sah.
The Board of
Commissioners
Meeting is held at
least every month
or at any time as
deemed necessary
by the President
Commissioner or
by 1/3 of the total
number of members
of the Board of
Commissioners or
upon a written request
from the Board of
Directors Meeting or
upon a request of 1/10
of the total number of
shares with a lawful
right to vote.
73
Rapat Dewan
KomisarisDireksi
adalah rapat yang
diselenggarakan
oleh Dewan
Komisaris dan
Direksi, sekurangkurangnya setiap
sebulan sekali
atau bilamana
dianggap perlu.
The Board of
CommissionersBoard
of Directors Meeting
refers to a meeting
held by the Board of
Commissioners and
the Board of Directors,
at least once in a
month or as deemed
necessary.
Nama
Name
Jabatan
Title
1
2
3
4
5
Ratna Rosita
Upik Rosalina Wasrin
Wahono Sumaryono
Effendi Rangkuti
Darmansyah
1
2
3
4
5
Supriyantoro
Dewi Fortuna Anwar
Wahono Sumaryono
Farid Wadjdi Husain
Basuki Ranto
1
2
3
4
5
Rusdi Rosman
Arief Budiman
Jisman Siagian
M. Wahyuli Syafari
Pujianto
Direktur Utama
Direktur Keuangan
Direktur Operasi & Supply Chain
Direktur Riset & Pengembangan Bisnis
Direktur Umum & Human Capital
74
Komisaris Utama
Komisaris
Komisaris
Komisaris Independen
Komisaris Independen
President Director
Finance Director
Operational & Supply Chain Director
Research & Business Development Director
General Affair & Human Capital Director
Kehadiran
Attendance
4/4
3/4
4/4
4/4
4/4
9/9
9/9
9/9
6/9
9/9
12/13
11/13
10/13
12/13
13/13
Direksi
Board Of Directors
Direksi
bertanggung
jawab
penuh
dalam
melaksanakan
tugasnya
untuk
kepentingan
Perseroan dalam mencapai maksud dan tujuannya.
Setiap anggota Direksi wajib dengan itikad baik dan
penuh tanggung jawab menjalankan tugasnya dengan
mengindahkan peraturan perundang-undangan yang
berlaku dan Anggaran Dasar Perseroan.
A. Direktur Utama
1. Bertanggung
jawab
mengendalikan
operasional Perseroan secara umum untuk
memastikan tercapainya tujuan Perseroan
sesuai dengan prinsip-prinsip Good Corporate
Governance;
2. Bertanggung jawab dalam koordinasi anggota
Direksi sehubungan dengan pengurusan
Perseroan;
3. Bertanggung jawab dalam kordinasi dan
sinergi antar rantai bisnis Perseroan dan
memantau jalannya operasi anak perusahaan;
4. Memantau jalannya pengawasan oleh Satuan
Pengawas Internal, Manajemen Risiko dan
Kepatuhan;
5. Merancang strategi korporasi sesuai dengan
visi dan misi Perseroan untuk meningkatkan
kinerja dan nilai Perseroan;
6. Mengarahkan dan mengendalikan operasi
Perseroan sejalan dengan rencana dan
kebijakan yang ada untuk mencapai tujuan
pertumbuhan dan profit;
7. Menetapkan kebijakan di dalam kerangka
penguatan
pondasi
bisnis
organisasi
Perseroan;
8. Menetapkan program Good Corporate
Governance;
9. Menyelenggarakan Rapat Umum Pemegang
Saham;
10. Terlaksananya realisasi investasi untuk
kelangsungan operasional Perseroan;
A. President Director
1. To assume responsibility to control operation
of the Company in general to ensure the
achievement of the Company in accordance
with the principles of Good Corporate
Governance;
2. To assume responsibility to coordinate with
the members of Board of Directors in relation
to the management of Company;
3. To assume responsibility in coordination and
synergy inter-business chain of the Company
and monitor the operation of subsidiary;
4. To monitor the operation of supervision
by Internal Control, Risk Management and
Compliance;
5. To design corporate strategy with the vision
and mission of the Company to improve
performance and Corporate value;
6. To direct and control the operation of
Company in line with the existing plan and
policy to attain the aims of growth and profit;
Direksi
bertanggung
jawab penuh
dalam
melaksanakan
tugasnya untuk
kepentingan
Perseroan dalam
mencapai maksud
dan tujuannya.
The Board of Directors
is fully responsible for
performing its tasks
for the Companys
interest in achieving
its purpose and
objective.
75
76
B. Direktur Keuangan
1. Memimpin, mengurus dan mengendalikan
operasional Direktorat Keuangan untuk
memastikan tercapainya tujuan Perseroan
sesuai dengan prinsip-prinsip Good Corporate
Governance;
2. Mewujudkan perolehan target, omset dan
profit SBU Kimia;
3. Bertanggung jawab terhadap tersedianya
tercapainya laporan keuangan sesuai dengan
peraturan yang telah ditetapkan;
4. Bertanggung jawab sepenuhnya atas
kebenaran dan ketepatan penyajian laporan
keuangan Perseroan;
5. Bertanggung jawab terhadap cash flow
Perseroan;
6. Bertanggung jawab terhadap pengendalian
keuangan yang efisien dan efektif sesuai
dengan rencana;
7. Tersusunnya RKAP Tahunan, Laporan
Tahunan Perseroan dan RJPP;
8. Melakukan analisa atas perkembangan
ekonomi termasuk pasar uang dan pasar
modal;
9. Bertanggung jawab terhadap terpenuhinya
kewajiban-kewajiban
Perseroan
sesuai
dengan jadwal dan terpenuhinya realisasi
investasi serta operasional di setiap direktorat
dan unit kerja;
10. Melakukan pembinaan, pengendalian, dan
pengembangan Human Capital Perseroan di
Direktorat Keuangan;
11. Melakukan pengendalian biaya-biaya bunga
dan risiko-risiko terhadap kurs.
12. Bertanggung jawab terhadap sistem IT dan
implementasi sistem IT.
B. Finance Director
1. To lead, manage and control operation
of the Finance Directorate to ensure the
achievement of aims of the Company in
accordance with the principles of Good
Corporate Governance;
2. To materialize the acquirement of target,
income and profit of SBU of Chemical;
3. To assume responsibility to the availability of
achieving financial statement with the given
regulation;
4. To assume full responsibility for the
authenticity and punctuality of presenting
financial statement of the Company;
5. To assume responsibility for cash flow of the
Company;
6. To assume responsibility for the control of
efficient and effective finance as planned;
77
78
Remunerasi Direksi
Rapat Direksi
Kehadiran
Jabatan
Title
Direktur Utama
Direktur Keuangan
Direktur Operasi & Supply Chain
Direktur Riset & Pengembangan Bisnis
Direktur Umum & Human Capital
President Director
Finance Director
Operational & Supply Chain Director
Research & Business Development Director
General Affair & Human Capital Director
Attendance
55/58
52/58
52/58
51/58
54/58
Subject
Rapat Direksi
dapat diadakan
setiap waktu
bilamana
dipandang perlu
atas permintaan
Direktur Utama
atau atas usul
dari sekurangkurangnya lebih
dari 1/3 dari
jumlah anggota
Direksi atau atas
permintaan Dewan
Komisaris dengan
menyebutkan
hal-hal yang akan
dibicarakan.
The Board of Directors
meeting can be
held anytime as
deemed necessary
upon request of the
President Director or
based on a proposal
from at least more
than 1/3 of the total
number of members
of the Board of
Directors or upon
request of the Board
of Commissioners by
mentioning matters to
be discussed.
79
Daftar Pelatihan & Seminar Dewan Komisaris & Direksi Tahun 2013
List of Board of Commissioners & Directors Trainning & Seminar in 2013
Nama
Jumlah
Peserta
Lama
Pelatihan
(Jam)
Keterangan
Name
Total
Participant
Periode of
Trainning
(Hour)
Description
16
16
No.
Perseroan
merupakan
Badan Usaha
Milik Negara
dengan komposisi
Pemegang Saham
Mayoritas adalah
Pemerintah
RI dengan
kepemilikan
saham sebesar
90,025%
sedangkan publik
sebesar 9,809%
dan Manajemen
serta karyawan
Perseroan sebesar
0,166%.
The Company
constitutes StateOwned Enterprises
with the compositions
of Majority
Shareholders namely
Government of
the Republic of
Indonesia with share
ownership of 90.025%,
meanwhile public in
the number of 9.809%
and Management
and employee of
the Company in the
number of 0.166%.
80
Dewan
Komisaris
Perseroan
Dewan
Komisaris
Perseroan
Dewan
Komisaris
Perseroan
Public
Trainning
Public
Trainning
Public
Trainning
Shareholder of Company
Pemerintah/
Government
90,02%
PEMEGANG
SAHAM
PERSEROAN/
SHAREHOLDER
OF COMPANY
Publik/
Public
9,81%
Komite Audit
Audit Committee
Basuki Ranto
Ketua Komite Audit
Basuki Ranto
Chairman of Audit Committe
Sobirun Ruswadi
Anggota Komite Audit
Sobirun Ruswadi
Member of Audit Committee
81
82
83
Dalam rangka
menegakkan
ketentuan
yang berkaitan
dengan prinsip
dan praktik Tata
Kelola Perusahaan
yang Baik (Good
Corporate
Governance),
maka Perseroan
telah membentuk
Komite GCG.
In order to uphold the
provisions relating
to the principle
and practice of
Good Corporate
Governance, the
Company has
established GCG
Committee.
84
Wahono Sumaryono
Anggota Komite Good Corporate Governance/Member of Good Corporate Governance Committee
Menyelesaikan pendidikan Apoteker di Fakultas
Farmasi Universitas Airlangga Surabaya tahun 1981,
meraih gelar Doktor bidang Biologi Farmasi dengan
gelar Doktor rerum naturalium pada 13 Juli 1990
di Technishce Universitaet Carolo Wilhelmina,
Braunschweig, Jerman, mendapat gelar Profesor
Riset Bidang Bioteknologi Farmasi, Januari 2006 dari
LIPI dan Guru Besar Kimia Bahan Alam dari Fakultas
Farmasi Universitas Pancasila Jakarta, Juni 2007.
Beliau pernah menjabat sebagai Pelaksana Tugas
Kepala Badan Pengkajian dan Penerapan Teknologi
(BPPT) tahun 2008 disamping sebagai Deputi
Kepala BPPT Bidang Teknologi Agroindustri dan
Bioteknologi tahun 2000-2010. Jabatan beliau saat
ini adalah sebagai Penasehat Deputi Kepala BPPT
Bidang Teknologi Agroindustri dan Bioteknologi
serta Peneliti Utama di Pusat Teknologi Farmasi dan
Medika BPPT.
Edy Suwahyo
Anggota Komite Good Corporate Governance/Member of Good Corporate Governance Committee
Menyelesaikan pendidikan apoteker di Universitas
Airlangga, Surabaya pada tahun 1980. Bergabung
dengan Perseroan sejak tahun 1981 di Surabaya.
Karir terakhirnya di Perseroan sebagai Manajer
Pembinaan dan Pengembangan SDM. Saat ini
bergabung di Pensiunan Kimia Farma sebagai
Pendiri Koperasi Mandiri Sejahtera.
85
Memastikan
bahwa manajemen
secara aktif
mensosialisasikan
Visi dan Misi
Perseroan serta
budaya Good
Corporate
Governance.
Ensuring that
the management
actively socializes the
Company Vision and
Mission and Good
Corporate Governance
culture.
86
1. Implementasi GCG
a. Laporan dan evaluasi kegiatan Komite GCG
tahun 2012.
b. Membantu Dewan Komisaris untuk evaluasi
Rencana Kerja dan Anggaran Perseroan tahun
2012.
c. Pengadaan jasa assessor independent &
mengusulkan calon assessor GCG untuk
tahun 2012.
d. Monitoring pelaksanaan assessment GCG.
e. Membahas hasil assessment dan evaluasi
tindak lanjut.
f. Monitoring sistem manajemen kinerja,
manajemen risiko, proses bisnis dan ERP
terintegrasi.
g. Evaluasi
Laporan
Kinera
Manajemen
pada Holding, PT Kimia Farma Trading &
Distribution, PT Kimia Farma Apotek, dan PT
Sinkona Indonesia Lestari.
h. Mempersiapkan rencana self assessment
GCG oleh assessor internal.
i. Mengikuti kunjungan Dewan Komisaris ke
Plant, Bisnis Manajer Apotek dan Cabang
Kimia Farma Trading & Distribution.
1. Implementation of GCG
a. Report and evaluation for the activity of GCG
Committee of 2012.
b. Helping the Board of Commissioners for the
evaluation of Action Plan and Budget of 2012.
3. Manajemen Risiko
a. Pembahasan Pedoman Umum dan Pedoman
Pelaksanaan Manajemen Risiko
b. Evaluasi berbagai potensi risiko yang dihadapi
Perseroan
c. Monitoring risiko rencana investasi di Holding
maupun anak perusahaan.
3. Risk Management
a. Discussion of General Guidelines and
Implementing Risk Management Guideline.
b. Evaluation of various potential risks
encountered by the Company.
c. Monitoring on risk of investment plan at
Holding or subsidiary
penerapan
87
Sekretaris Perusahaan
Corporate Secretary
88
Djoko Rusdianto
Djoko Rusdianto
1. Managing
the
availability
of
external
communication access through the Companys
website management to meet the interests of the
investors and customers and to hold meetings,
lobbies and prepare annual reports to provide
public information that stakeholders need.
2. Managing the obligation to the provisions of
transparency and accuracy of information by
preparing the Companys documents relating to
the obligation as an public-listed company, among
Mengelola
komunikasi
internal dengan
menyelenggarakan penerbitan
majalah internal
Gema Kaef
Managing internal
communication by
issuing the internal
magazine Gema Kaef
89
Satuan Pengawas
Intern (SPI)
Perseroan
merupakan
partner strategis
dalam aspek
pengawasan dan
pengendalian
internal bagi
Direksi dan jajaran
manajemen
lainnya
serta dalam
menjalanakan
fungsi
pengawasan
secara fungsional
berkoordinasi
dengan Komite
Audit.
Internal Control of
the Company forms
strategic partner in
the aspects of internal
supervision and
control of the Board
of Directors and other
management line to
carry out the function
of supervision
functionally in
coordination with the
Audit Committee.
90
Internal Control
1. Pelaksanaan
audit
internal
berdasarkan
identifikasi risiko dengan melakukan desk audit
terhadap seluruh objek audit, meningkatkan
koordinasi dengan anak perusahaan dalam
rangka permintaan data untuk pelaksanaan desk
audit serta menyusun jadwal site audit dan Tim
Audit berdasarkan hasil desk audit.
2. Pemanfaatan sistem teknologi informasi secara
optimal dalam rangka pencegahan dini (early
warning) dengan meningkatkan koordinasi
Ineng Setiasih
Ineng Setiasih
91
Pelaksanaan audit
internal berbasis
risiko (risk based
audit) dengan
meningkatkan
koordinasi dengan
Unit Kepatuhan
dan Manajemen
Risiko untuk
mendapatkan
profil risiko pada
masing-masing
Unit Kerja.
The implementation
of risk based audit
is by improving
coordination with
Compliance Unit and
Risk Management to
obtain the risk profile
at each Working Unit
92
1. Risiko Strategis
1. Strategic Risks
Risiko strategis
merupakan
peristiwaperistiwa yang
disebabkan oleh
faktor eksternal
seperti perubahan
kondisi ekonomi
makro, hukum
dan regulasi,
sosial/masyarakat,
politik dan/atau
faktor lain yang
mempengaruhi
keberlangsungan
Perseroan.
Strategic risks are
the events due to
external factor such as
the change of macro
economy condition,
laws and regulation,
social/community,
politics and/or other
factors affecting the
survival of Company.
93
Risiko keuangan
merupakan
peristiwa-peristiwa
yang disebabkan
oleh pergerakan
atau fluktuasi
variabel-variabel
pasar serta
perubahan kurs
valuta asing,
harga bahan
baku, tingkat
suku bunga, biaya
transportasi dan
distribusi, serta
gagal bayar dari
pelanggan.
Financial risk is the
events caused by the
fluctuation of market
variable and change of
foreign exchange rate,
price of raw materials,
interest rate, transport
and distribution costs,
and default from the
customer.
94
Dukungan
infrastruktur
untuk
meningkatkan pangsa pasar luar negeri
Risiko ketidaksiapan infrastruktur dalam
mengantisipasi permintaan pasar di luar
negeri berdampak pada pencapaian sasaran
pertumbuhan penjualan Perseroan. Risiko ini
ditangani dengan meningkatkan kapasitas dan
kapabilitas SDM serta mendorong aktivitas
produksi yang terencana dan terintegrasi.
2. Risiko Keuangan
2. Financial Risk
3. Risiko Operasional
3. Operation Risk
Risiko operasional
merupakan
peristiwaperistiwa yang
disebabkan oleh
tidak cukupnya
dan/atau tidak
berfungsinya
proses internal/
prosedural,
kesalahan
manusia,
kegagalan
sistem, atau
adanya problem
eksternal yang
mempengaruhi
operasional
Perseroan.
Operation risk is the
event caused by the
insufficiency and/or
absence of functioning
the internal process/
procedure, human
error, system failure,
or any external
problem affecting the
Companys operation.
95
Dalam rangka
mencapai Visi dan
Misi, Perseroan
senantiasa
melakukan
Evaluasi Kinerja
berbasis Balance
Score Card (BSC).
In order to achieve
the vision and
mission, the Company
continuously
conducts performance
evaluation based on
Balance Score Card
(BSC).
96
Performance Management
Performance Management
2. Approach
Using
PMS
(Performance
Management System)
This approach is to find out how the business
results achieved, in other words, this approach is
in the evaluation of the process to attainment the
results.
Management
Review merupakan
sarana bagi
setiap Divisi/Unit
Kerja dan anak
perusahaan dalam
mendeteksi secara
dini berbagai
kemungkinan
yang dapat
menghambat
proses kinerja
dan sekaligus
merupakan proses
pembelajaran yang
berkelanjutan
untuk peningkatan
kinerja
Perseroan secara
menyeluruh.
Sepanjang
tahun
2013,
Perseroan
telah
melaksanakan Management Review sebanyak 4
(empat) kali yang diikuti oleh Dewan Komisaris,
Direksi Perseroan dan anak perusahaan, General
Manager dan Manager.
Keterbukaan Informasi
Information Disclosure
Management Review
is the facility for any
Division/Working
Unit and subsidiary to
earlier detect various
possibilities that
can hamper process
of performance
and constitute
the sustainable
learning process for
the improvement
of Companys
performance as a
whole.
97
Perseroan
senantiasa
berkomitmen
untuk
menyediakan
produk-produk
dan pelayanan
kesehatan dengan
nilai (baik harga
dan kualitas)
yang berkualitas
serta aman bagi
konsumen.
The Company is
always committed
to providing health
products and services
at value (both in terms
of price and quality)
and safe to consumers.
98
Program Kemitraan
Partnership Program
Program
Kemitraan
dilaksanakan
dengan
memberikan pinjaman kredit lunak kepada apotek,
toko obat, pengusaha kecil terdiri dari sektor
perdagangan, jasa, industri dan koperasi secara
bergulir. Untuk memperkecil risiko piutang macet,
dilakukan evaluasi dan pemantauan usaha penerima
pinjaman secara reguler sehingga keberlangsungan
program ini dapat dicapai. Di samping memberikan
bantuan permodalan, pembinaan dilakukan dengan
memberikan pelatihan dan mengikuti pameranpameran di berbagai daerah.
Sejalan dengan
budaya
perusahaan I
CARE, Perseroan
menyikapi
permasalahan
HIV/AIDS dengan
memproduksi
obat Antiretroviral
(ARV).
In line with its
corporate culture
I CARE, the
Company deals
with any HIV/AIDS
issues by producing
Antiretroviral (ARV)
medicines.
99
Program
Kemitraan
dilaksanakan
dengan
memberikan
pinjaman kredit
lunak kepada
apotek, toko obat,
pengusaha kecil
terdiri dari sektor
perdagangan,
jasa, industri dan
koperasi secara
bergulir.
Partnership Program
is implemented by
giving soft credit
loan to pharmacies,
drugstores, small
enterprises
comprising the trade,
service, industry and
cooperative sectors on
a rolling basis.
Keterangan
Industri
Perdagangan
Pertanian
Peternakan
Perkebunan
Perikanan
Jasa
Jumlah/Total
Description
Industry
Trading
Agriculture
Farming
Plantation
Fishery
Services
Jumlah Rp
Jumlah Mitra
Binaan
Total Rp
420
100
110
630
Total Partner
7
1
4
12
REALISASI PROGRAM KEMITRAAN BERDASARKAN WILAYAH TAHUN 2013 (dalam Juta Rupiah)
REALIZATION OF PARTNERSHIP PROGRAM BASED ON AREA OF 2013 (in Million Rupiah)
No
1
2
3
4
5
6
100
Propinsi
Apotek/Toko Obat
Usaha Kecil
Koperasi
Pharmacy/Drugstore
Small Business
Coopertive
Jml Mitra
Binaan
Jml Pinjaman
(Rp)
Jml Mitra
Binaan
Jml Pinjaman
(Rp)
Jml Mitra
Binaan
Jml Pinjaman
(Rp)
Total
Partner
Total Lending
Total
Partner
Total
Lending
Total
Partner
Total
Lending
1
3
4
1
1
10
25
65
75
50
15
230
1
1
2
300
100
400
Uraian
1
Bencana Alam
2
Pendidikan & Pelatihan
3
Kesehatan
4
Sarana & Prasarana Umum
5
Sarana Ibadah
6
Pelestarian Alam
7
Pengentasan Kemiskinan
Jumlah/Total
No
Uraian
1
Bencana Alam
2
Pendidikan & Pelatihan
3
Kesehatan
4
Sarana & Prasarana Umum
5
Sarana Ibadah
6
Pelestarian Alam
7
Pengentasan Kemiskinan
Jumlah/Total
Description
Natural Disaster
Education & Trainning
Health
Public Facility
Worship Facility
Natural Reservation
Poverty Reduction
Description
Natural Disaster
Education & Trainning
Health
Public Facility
Worship Facility
Natural Reservation
Poverty Reduction
Sepanjang
tahun
2013,
Perseroan
telah
melaksanakan kegiatan sosial sebagai bentuk dari
tanggung jawab sosial dan kepedulian Perseroan
terhadap masyarakat di lingkungan Perseroan.
Bentuk kepedulian tersebut antara lain, pembinaan
masyarakat dalam pengelolaan sampah sehingga
bisa menjadi kompos dan bisa dimanfaatkan untuk
pupuk tanaman serta bisa menjadi tambahan
penghasilan karena kompos tersebut sudah bisa
dijual di pasaran. Kegiatan ini sudah berjalan selama
2 (dua) tahun dan hingga sekarang kegiatan tersebut
masih terus dijalankan.
Jumlah
Penyaluran
Total
Distribution
95,4
375,8
608,1
60,8
303,4
35,8
152,8
1.632,1
Sumut
8,2
8,2
5,0
50,9
10,5
7,5
73.9
Jumlah
Penyaluran
Total
Distribution
20,0
70,8
778,0
124,4
1,5
20,0
1.014,7
DKI
Jakarta
80,0
339,7
361,0
40,8
41,2
15,7
6,6
885,0
Jabar
Jateng
15,4
31,1
136,0
12,5
121,9
(20,0)
69,8
366,7
32,7
7,5
79,8
75,7
195,7
DIY
19,3
50,0
32,6
0,7
102,6
Banten
16,8
20,0
36,8
Bali
20,0
46,5
16,4
82,9
Sulut
62,0
62,0
Sulsel
81,0
81,0
377,3
50,0
1,5
428,8
101
Kesehatan &
Keselamatan Kerja
serta Lingkungan,
yang sering
disebut dengan
K3L, merupakan
bagian dari
nilai-nilai yang
dimiliki oleh
Perseroan dalam
memberikan
kontribusi
untuk menjaga
lingkungan.
The Work Health
& Safety and
Environment,
frequently called
HSE, constitutes
a part of values
that the Company
has in providing
contributions
to preserve the
environment.
102
Companys Acknowledgement of
Employees Rights
Anak Perusahaan
Subsidiaries
PT Kimia Farma
Trading & Distribution
komposisi saham
Shares Composition
103
Sebagai penyedia
Jasa Layanan
Distribusi, KFTD
menyalurkan
aneka produk dari
Perseroan, produk
dari keagenan
lainnya, serta
produk-produk
non-keagenan.
As supplier of
Distribution Service,
KFTD distributes
various products
of the Company,
products from other
principals, and nonprincipal products.
Etikal/Ethical
CHP/OTC (Chemical/Herbal)
Branded
Hospital Equipment
Cosmetics/Toiletries
Generics (OGB)
Body Care
Contraceptive
Narcotics
Vitamins, Medicine
Raw Materials
Biological Products
104
human resources
Armada
transportasi
yang terintegrasi
dengan sistem
informasi, juga
merupakan bagian
yang penting
dalam mendukung
kelancaran
aktivitas KFTD.
Transport fleet
integrated with the
information system
also constitutes an
important part in
supporting smooth
activities carried out
by KFTD.
105
KFA sejak
tahun 2011 telah
melakukan
program
transformasi dan
mengubah visi
Perseroan dari
jaringan ritel
farmasi menjadi
jaringan layanan
kesehatan yang
terkemuka
dan mampu
memberikan
solusi kesehatan
masyarakat di
Indonesia.
KFA has conducted
transformation
program since 2011
and changed vision
of the company from
pharmaceutical retail
network to leading
medical service
network and able to
solve public health in
Indonesia.
106
Kegiatan Usaha
Business Activity
Human Resource
Sedangkan
pelayanan
klinik
kesehatan
menggunakan standar Kementerian Kesehatan
Republik Indonesia tentang Klinik dan pelayanan
laboratorium klinik menggunakan standar Good
Laboratory Practice (GLP) dan prinsip-prinsip
akreditasi dari Komite Akreditasi Laboratorium
Kesehatan (KALK) Kementerian Kesehatan Republik
Indonesia.
107
108
109
110
Kegiatan Usaha
Business Activity
Human Resource
Untuk Tahun yang Berakhir pada Tanggal 31 Desember 2013 dan 2012
Daftar Isi
Table of Contents
112
113-115
116-117
118
119
120
121-209
111
112
113
114
115
31 / 12 / 2013
2d,2e,2p, 3
Pihak ketiga
Piutang lain-lain
2f, 5
Persediaan
Setelah dikurangi penyisihan persediaan
usang
masing-masing
sebesar
Rp 18.172.074.618 dan Rp 16.472.881.709
pada tanggal 31 Desember 2013 dan 2012
2g, 6, 17
Uang muka
7
Pajak dibayar dimuka
2q, 8a
Biaya dibayar dimuka
2h, 9
Jumlah Aset Lancar
2f, 10
2b, 2f, 11
2i,2j,12
2i,2j,13
2m, 14
2j, 15
2n, 16
2s, 8d
JUMLAH ASET
116
394.149.909.832
61.534.147.809
485.042.276.146
7.644.556.388
640.909.360.172
1.805.960.726
184.697.561.679
34.830.841.785
1.810.614.614.537
523.375.893
380.977.729
316.497.879.806
103.770.489.171
354.958.026.078
5.738.392.231
530.417.299.657
4.610.409.911
165.200.810.228
24.605.092.082
1.505.798.399.164
1.141.880.429
921.912.000
498.644.378.133
9.301.868.998
631.756.211
3.412.069.215
109.147.189.798
39.283.318.376
661.324.934.353
449.140.317.883
9.301.868.998
819.700.633
2.582.281.825
68.285.275.301
38.355.944.552
570.549.181.621
2.471.939.548.890
2.076.347.580.785
CURRENT ASSETS
Cash and cash equivalents
Trade receivables
Related parties
Third parties
Other receivables
Inventories
Advance payments
Prepaid taxes
Prepaid expenses
Total Current Assets
Investment in associates
Fixed Assets,
Unused assets
Deferred charges
Intangible assets
Other assets
Deferred tax assets
Total Non-Current Assets
TOTAL ASSETS
31 / 12 / 2013
31 / 12 / 2012
2f, 17
47.375.830.919
17.377.108.766
2f, 18
2f, 2p, 18
2s, 8b
19
20
2k, 21
22
21.721.859.363
456.169.891.947
52.708.653.939
2.077.643.896
117.961.455.449
1.735.823.535
46.371.989.506
36.884.377.032
304.248.660.515
46.608.327.874
1.665.285.810
91.281.052.262
4.086.850.879
35.032.572.088
CURRENT LIABILITIES
Bank loan
Account payables
Related parties
Third parties
Taxes payable
Advance receipt from customers
Accrued expenses
Lease liabilities short term
Other current liabilities
746.123.148.554
537.184.235.226
99.588.762.093
1.872.949.262
91.239.848.054
6.389.807.839
NON-CURRENT LIABILITIES
Employee benefit obligations
Lease liabilities long term
101.461.711.355
97.629.655.893
Jumlah Liabilitas
847.584.859.909
634.813.891.119
Total Liabilties
EKUITAS
EKUITAS YANG DAPAT
DIATRIBUSIKAN KEPADA
PEMILIK ENTITAS INDUK
Modal saham
modal dasar sebanyak 20.000.000.000
saham terdiri dari : 1 saham seri A
Dwiwarna dan 19.999.999.999 saham
seri B. Modal ditempatkan dan disetor
penuh 5.554.000.000 saham terbagi atas
1 saham seri A Dwiwarna dan
5.553.999.999 saham seri B dengan nilai
nominal Rp 100 per saham
Tambahan modal disetor
Selisih transaksi restrukturisasi Entitas
Sepengendali
Tambahan modal disetor
Saldo laba
Ditentukan penggunaannya
Belum ditentukan penggunaannya
2r, 23
2k, 21
26
555.400.000.000
555.400.000.000
25
10.084.641.850
10.084.641.850
2m, 27
43.579.620.031
43.579.620.031
35
784.611.229.538
214.549.154.260
612.299.243.565
205.133.316.635
1.608.224.645.679
1.426.496.822.081
16.130.043.302
15.036.867.585
Jumlah Ekuitas
1.624.354.688.981
1.441.533.689.666
2.471.939.548.890
2.076.347.580.785
24
EQUITY
EQUITY ATTRIBUTABLE
TO OWNERS
OF THE ENTITY
Share capital
Authorized-20,000,000,000 shares
consisting of 1 serie A Dwiwarna share
and 19,999,999,999 serie B shares
Issued and fully paid 5,554,000,000
shares consisting of 1 serie A
Dwiwarna share and 5,553,999,999
serie B shares with amount
Rp 100 per share
Paid in capital
Difference in restructuring Entities
transactions
Addition paid in capital
Retained Earnings
Specified use
Unspecified use
Total equity attributable to owners of
the entity
NON-CONTROLLING INTEREST
Total Equity
TOTAL LIABILITIES AND EQUITY
117
31/12/2012
PENJUALAN
4.348.073.988.385
(3.055.921.946.994)
Catatan/
Notes
31/12/2012
2r, 2p, 28
3.734.241.101.309
SALES
(2.559.074.130.367)
1.175.166.970.942
GROSS PROFIT
2r, 29
1.292.152.041.391
43.681.718.265
(1.042.618.886.755)
811.575.630
33
2r, 30
2r, 32
11
(261.374.648)
LABA USAHA
293.765.073.883
Beban Keuangan
(9.639.641.584)
31
24.135.411.087
(912.599.414.375)
(1.546.112.212)
-
Other income
Operating expenses
Income (expense) on foreign
exchange - net
Profit / loss from associated
entities and / or joint venture
285.156.855.442
OPERATING INCOME
(6.872.403.387)
Finance cost
278.284.452.055
(72.520.454.677)
284.125.432.299
(68.483.102.322)
215.642.329.977
205.763.997.378
OTHER COMPREHENSIVE
INCOME (EXPENSE)
205.133.316.635
630.680.743
36,93
PENDAPATAN (BEBAN)
KOMPREHENSIF LAIN
Laba yang dapat dapat diatribusikan
kepada::
Pemilik Entitas induk
Kepentingan non pengendali
214.549.154.260
1.093.175.717
118
2s, 8c
38,63
24
2t, 34
119
550.400.000.000
43.579.620.031
43.579.620.031
43.579.620.031
Laba
Bina lingkungan
Cadangan umum
Dividen
550.400.000.000
Laba
Cadangan umum
Program kemitraan
Bina lingkungan
550.400.000.000
Modal Saham /
Share Capital
10.084.641.850
10.084.641.850
10.084.641.850
-
784.611.229.538
172.311.985.973
-
214.549.154.260
1.608.224.645.679
214.549.154.260
214.549.154.260
(2.051.333.167)
(30.769.997.495)
1.426.496.822.081
205.133.316.635
(3.453.309.749)
(3.453.309.749)
10.084.641.850
(34.353.097.492)
1.252.659.832.500
Total / Total
1.624.354.688.981
215.642.329.977
(2.051.333.167)
(30.769.997.495)
1.441.533.689.666
205.763.997.378
(3.453.309.749)
(3.453.309.749)
24.487.725.452
(34.353.097.492)
1.252.662.935.740
Total / Total
Earning
Community development
Dividend
General reserve
Community development
Net income
General reserve
Partnership program
16.130.043.302
1.093.175.717
15.036.867.585
630.680.743
14.403.083.602
-
3.103.240
Kepentingan
Non
Pengendali / Non
Controlling
Interest
(2.051.333.167)
(172.311.985.973)
(30.769.997.495)
205.133.316.635
(130.541.770.468)
(3.453.309.749)
(3.453.309.749)
(34.353.097.492)
205.133.316.635
171.922.739.372
612.299.243.565
130.541.770.468
481.757.473.097
31/12/2012
31/12/2012
4.563.133.300.516
(3.076.539.056.023)
(698.196.566.046)
(498.715.350.944)
(9.639.641.584)
(99.023.130.401)
204.714.162
51.620.463.956
20.938.931.097
4.018.454.048.266
(2.765.002.697.480)
(581.786.652.168)
(463.585.368.880)
(6.872.403.386)
(74.800.158.611)
374.769.890
82.374.149.407
21.456.967.453
253.783.664.733
230.612.654.491
3.703.407.330
2.553.911.325
(89.030.076.719)
(106.352.855.445)
18.590.496.950
279.559.623
-
(52.765.067.722)
(20.065.859.043)
6.049.403.894
(921.912.000)
31.450.382
(172.809.468.261)
(65.118.073.164)
29.998.722.154
(30.769.803.148)
(2.551.085.452)
(8.864.606.946)
(34.352.788.065)
(5.165.060.620)
(3.322.166.446)
(48.382.455.631)
77.652.030.026
316.497.879.806
394.149.909.832
120
117.112.125.697
199.385.754.109
316.497.879.806
1. UMUM
1.
a. Pendirian Entitas
GENERAL
a. Establishment
6
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
121
1. UMUM (Lanjutan)
1.
a. Establishment (Continued)
(1)
(2)
a) Provide,
producing
and
processing
of chemical, pharmaceutical, biological
and
other
materials
necessary
to
manufacture pharmaceutical, inventories,
contraceptives,
cosmetics,
traditional
medicines, medical equipment, food and
beverages and other products includes
engages in the plantation and exploration
industries that are related to such production.
b) Memproduksi
pengemas
dan
bahan
pengemas, mesin dan peralatan serta sarana
pendukung lainnya, baik yang berkait dengan
industri farmasi maupun industri lainnya;
122
GENERAL (Continued)
1. UMUM (Lanjutan)
1.
GENERAL (Continued)
a. Establishment (Continued)
c) Menyelenggarakan
kegiatan
pemasaran,
perdagangan dan distribusi dari hasil produksi
seperti di atas, baik hasil produksi sendiri
maupun hasil produksi pihak ketiga, termasuk
barang umum, baik di dalam maupun di luar
negeri, serta kegiatan-kegiatan lain yang
berhubungan dengan usaha Entitas;
b. Public Offering
c. Entitas Anak
c. Subsidiaries
8
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
123
1. UMUM (Lanjutan)
1.
GENERAL (Continued)
c. Subsidiaries (Continued)
Persentase Kepemilikan /
Percentage of Ownership
2013
2012
Entitas Anak /
Subsidiaries
Domisili /
Domicile
Kegiatan Usaha /
Activities
Mulai Beroperasi /
Date of Operations
Jakarta
Apotek (Ritel) /
Drugstore
4 Januari 2003 /
January 4, 2003
99,99%
99,99%
Jakarta
Distribusi Obat-obatan /
Medicine Distribution
4 Januari 2003 /
January 4, 2003
99,99%
99,99%
PT Sinkona Indonesia
Lestari
Subang
Pabrik Kina/Quinine
Factory
25 Oktober 1986 /
October 25, 1986
56,02%
56,02%
PT Kimia Farma
Diagnostika *
Jakarta
Layanan Kesehatan /
Health Services
1 Januari 2010 /
January 1, 2010
99,00%
99,00%
Persentase Kepemilikan /
Percentage of Ownership
2012
2011
Entitas Anak /
Subsidiaries
Domisili /
Domicile
Kegiatan Usaha /
Activities
Mulai Beroperasi /
Date of Operations
Jakarta
Apotek (Ritel) /
Drugstore
4 Januari 2003 /
January 4, 2003
99,99%
99,99%
Jakarta
Distribusi Obat-obatan /
Medicine Distribution
4 Januari 2003 /
January 4, 2003
99,99%
99,99%
PT Sinkona Indonesia
Lestari
Subang
Pabrik Kina/Quinine
Factory
25 Oktober 1986 /
October 25, 1986
56,02%
15,00%
PT Kimia Farma
Diagnostika *
Jakarta
Layanan Kesehatan /
Health Services
1 Januari 2010 /
January 1, 2010
99,00%
99,00%
2012
Rp
699.694.772.747
530.207.645.060
PT KFTD
835.521.670.772
707.408.505.633
PT SIL
121.485.073.955
87.917.178.566
20.507.162.574
17.024.636.002
124
1. UMUM (Lanjutan)
1.
GENERAL (Continued)
c. Subsidiaries (Continued)
Berdasarkan
hasil
Rapat
Umum Pemegang
Saham Luar Biasa yang diaktakan No.1 tanggal
1 November 2002 dari Imas Fatimah, S.H., notaris di
Jakarta, para pemegang saham telah menyetujui
restrukturisasi usaha Entitas dengan membentuk 2
(dua) Entitas Anak. Pada tanggal 4 Januari 2003
Entitas membentuk 2 (dua) Entitas Anak yaitu, PT
Kimia Farma Apotek dan PT Kimia Farma Trading &
Distribution (PT KFTD).
10
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
125
1. UMUM (Lanjutan)
d.
1.
d.
Komisaris Utama
Komisaris
:
:
Komisaris Independen
Direktur Utama
Direktur
:
:
2013
dr. Supriyantoro, MA
Prof. Dr. Wahono Sumaryono, Apt., APU.
Sdri. Prof. Dr Dewi Fortuna Anwar
dr. Farid Wadjdi Husain
Dr. Basuki Ranto MM
2012
dr. Ratna Rosita, MPHM.
Prof. Dr. Wahono Sumaryono, Apt., APU.
Dr. IR. Upik Rosalina Wasrin, DEA.
Mayjen TNI (Purn) Effendi Rangkuti, SH.
Laksda TNI (Purn) dr. H. Darmansyah.
Drs. Pujianto.
Drs. Pujianto.
GENERAL (Continued)
:
:
President Commissioner
Commissioner
Independent Commissioner
:
:
President Director
Directors
:
:
:
:
Corpotare Secretary
Corporate Secretary
11
126
1. UMUM (Lanjutan)
1.
GENERAL (Continued)
d. Board of commissioners, Directors, Audit Committee
and Employees (Continued)
12
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
127
2.
13
128
2.
b. Prinsip-prinsip Konsolidasian
14
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
129
2.
c. Kombinasi Bisnis
c. Bussines Combination
Kas dan setara kas terdiri dari kas dan bank, dan
semua deposito berjangka yang tidak dibatasi
penggunaannya, yang jatuh tempo dalam tiga bulan
atau kurang sejak tanggal penempatan.
130
2.
e. Instrumen Keuangan
16
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
131
2.
Aset Keuangan
Financial Assets
Pengakuan awal
Aset Keuangan dalam lingkup PSAK No. 55 (Revisi
2011) diklasifikasikan sebagai; (i) aset keuangan yang
diukur pada nilai wajar melalui laporan laba atau rugi,
(ii) pinjaman yang diberikan dan piutang, (iii) investasi
yang dimiliki hingga jatuh tempo, atau (iv) aset
keuangan tersedia untuk dijual, klasifikasi ini
tergantung dari tujuan perolehan aset tersebut.
Initial recognition
Financial assets within the scope of SFAS No. 55
(Revised 2011) are classified as: (i) financial assets at
fair value through profit or loss, (ii) loans and
receivables, (iii) investments held to maturity, or (iv)
financial assets available for sale, this classification
depends on the purpose of that asset.
17
132
of
its
2.
18
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
133
2.
19
134
2.
Liabilitas Keuangan
Financial Liabilities
20
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
135
2.
21
136
2.
dari
Wajar
22
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
137
2.
23
138
2.
1. Aset Keuangan
1. Financial assets
24
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
139
2.
2. Liabilitas Keuangan
2. Financial Liabilities
Keuangan
Piutang Usaha
Accounts Receivables
25
140
2.
pengendalian
26
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
141
2.
g.
g. Persediaan
g. Inventories
h.
Prepaid Expenses
i. Aset Tetap
i.
Fixed Assets
27
142
2.
i.
Metode penyusutan /
Depreciation method
garis lurus (straight line)
12,5% - 25%
25%
Penyusutan
tanaman
menghasilkan
dihitung
berdasarkan jangka waktu tanaman yang ditentukan
oleh pertumbuhan vegetatif dan berdasarkan taksiran
manajemen sebagai berikut:
Tahun pertama
Tahun kedua
Tahun ketiga
Tahun keempat
Tahun kelima
25% - 50%
Tarif Penyusutan /
Rate of Depreciation
2%
3%
4%
6%
85%
First year
Second year
Third year
Fourth year
Fifth year
28
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
143
2.
j. Intangible Assets
k. Sewa
k. Lease
144
2.
k. Sewa (Lanjutan)
Aset
sewa
pembiayaan
disusutkan
dengan
menggunakan metode yang setara dengan aset yang
dimiliki secara langsung.
m. Beban ditangguhkan
m. Deferred Expenses
30
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
145
2.
n. Aset Lain-lain
n. Other Assets
31
146
2.
2.
1 Dollar Amerika
1 Dollar Singapura
1 EURO Eropa
1 Ringgit Malaysia
31 / 12 / 2013
31 / 12 / 2012
12.189,00
9.628,12
16.821,51
3.707,69
9.670,00
7.907,12
12.809,86
3.159,63
Beban Keuangan
Financial Expenses
32
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
147
2.
2.
q. Imbalan Kerja
q. Employee Benefits
33
148
2.
s. Pajak Penghasilan
s. Income Tax
34
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
149
2.
u. Informasi Segmen
u. Segmented Information
150
2.
2.
Business
segment
presents
the
Entity
and
Subsidiaries financial information that are classified
according to products or services earned and each
component has different risks and compensation from
the other business segments.
v. Investments in Associates
151
2.
Penyusunan
laporan
keuangan
konsolidasian
berdasarkan prinsip akuntansi yang berlaku umum
mengharuskan manajemen untuk menggunakan
estimasi, pertimbangan dan asumsi atas nilai tercatat
aset dan liabilitas yang tidak tersedia pada sumbersumber lain. Estimasi dan asumsi tersebut berdasarkan
pengalaman historis dan faktor lain yang
dipertimbangkan relevan.
37
152
3.
31 / 12 / 2013
Rupiah
Dollar Amerika Serikat
Bank
Pihak Pihak Berelasi
Rupiah
PT Bank Mandiri (Persero) Tbk
PT Bank Rakyat Indonesia (Persero)
Tbk.
PT Bank Pembangunan Daerah
PT Bank Negara Indonesia (Persero)
Tbk.
PT Bank BRI Syahriah
PT Bank Syariah Mandiri
Sub Jumlah
Dollar Amerika Serikat
PT Bank Mandiri (Persero) Tbk
Sub Jumlah
Pihak Ketiga
Rupiah
PT Bank Bukopin Tbk
PT Bank of Tokyo
PT Bank CIMB Niaga
PT Bank Central Asia Tbk.
PT Bank OCBC-NISP Tbk
PT Bank Muamalat Indonesia
Sub Jumlah
Mata uang asing
PT Bank OCBC-NISP Tbk
Sub Jumlah
Jumlah Bank
Deposito Jangka Pendek
Pihak Pihak Berelasi
Rupiah
PT Bank Tabungan Negara (Persero)
Tbk.
PT Bank Mandiri (Persero) Tbk
PT Bank Jabar Banten Tbk
Pihak Ketiga
Rupiah
Bank BTPN
PT Bank Yudha Bahakti
PT Bank Victoria
Jumlah Deposito
Jumlah
Tingkat Bunga Deposito
12.466.863.935
98.776.189
12.565.640.124
17.291.175.314
86.401.450
17.377.576.764
210.840.107.926
181.650.290.463
13.523.358.812
66.439.937.055
10.495.042.250
50.110.996.447
8.492.200.810
984.819.239
202.630.747
300.483.054.589
9.113.462.414
1.469.087.508
615.657.478
253.454.536.560
9.288.741.947
9.288.741.947
5.702.154.788
5.702.154.788
7.074.737.316
3.526.995
197.116.596
83.049.035
1.442.764.408
7.131.128.379
15.932.322.729
11.248.950.550
149.135.107
46.464.917
1.466.595.399
7.049.420.585
3.045.136
19.963.611.694
880.150.443
880.150.443
326.584.269.708
279.120.303.041
10.000.000.000
10.000.000.000
10.000.000.000
20.000.000.000
-
10.000.000.000
10.000.000.000
5.000.000.000
55.000.000.000
394.149.909.832
20.000.000.000
316.497.879.806
6,00% - 8,25%
4,00% - 7,85%
Cash
IDR
USD
Bank
Related Parties
IDR
PT Bank Mandiri (Persero) Tbk
PT Bank Rakyat Indonesia
(Persero) Tbk.
PT Bank Pembangunan Daerah
PT Bank Negara Indonesia
(Persero) Tbk.
PT Bank BRI Syariah
PT Bank Syariah Mandiri
Sub Total
USD
PT Bank Mandiri (Persero) Tbk
Sub Total
Third Parties
IDR
PT Bank Bukopin Tbk
PT Bank of Tokyo
PT Bank CIMB Niaga
PT Bank Central Asia Tbk.
PT Bank OCBC-NISP Tbk
PT Bank Muamalat Indonesia
Sub Total
Foreign currency
PT Bank OCBC-NISP Tbk
Sub Total
Total Bank
Short Term Deposit
Related Parties
IDR
PT Bank Tabungan Negara
(Persero) Tbk.
PT Bank Mandiri (Persero) Tbk
PT Bank Jabar Banten Tbk
Third Parties
IDR
Bank BTPN
PT Bank Yudha Bahakti
PT Bank Victoria
Total Deposit
Total
Deposit Interest Rate
38
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
153
3.
4. PIUTANG USAHA
Pihak Pihak Berelasi
PT Asuransi Kesehatan Indonesia
(Persero)
PT Perusahaan Listrik Negara
(Persero)
PT Angkasa Pura (Persero)
PT Perkebunan Nusantara IV
(Persero)
PT Rajawali Nusindo
PT Jamsostek (Persero)
PT Pertamina (Persero)
PT Timah (Persero) Tbk
PT Aneka Tambang (Persero) Tbk.
PT Indofarma Global Medika
PT Telekomunikasi Indonesia
Lain-lain (di bawah
Rp1.000.000.000)
Jumlah
Penyisihan kerugian penurunan
nilai
Jumlah-bersih
4.
31/ 12 / 2013
ACCOUNT RECEIVABLES
31 / 12 / 2012
27.455.042.487
14.780.402.542
9.854.718.156
6.183.808.509
4.375.195.262
3.178.489.873
2.235.420.928
288.093.417
1.965.492.208
1.322.356.643
1.321.767.990
1.240.162.106
975.804.967
452.270.594
1.102.982.690
8.319.741.328
41.032.678.107
2.046.056.531
1.587.313.378
934.193.360
1.365.583.048
19.966.713.468
1.184.569.513
12.460.426.192
61.564.024.304
104.065.258.993
(29.876.495)
(294.769.822)
61.534.147.809
103.770.489.171
Pihak Ketiga
Lokal
Jawa
Sumatera
Sulawesi, Maluku dan Papua
Bali dan Nusa Tenggara
Kalimantan
Ekspor
Jumlah Piutang Usaha pihak
ketiga
Penyisihan kerugian penurunan nilai
Jumlah bersih pihak
ketiga bersih
Jumlah
265.524.414.243
54.796.314.682
34.154.317.418
16.643.600.750
12.473.619.583
383.592.266.676
112.687.069.087
238.406.767.952
43.390.983.404
29.422.290.984
18.819.795.515
9.891.181.683
339.931.019.538
33.283.191.650
496.279.335.763
373.214.211.188
(11.237.059.617)
(18.256.185.110)
485.042.276.146
354.958.026.078
546.576.423.955
458.728.515.248
39
154
Related Parties
Local
Java
Sumatera
Sulawesi, Maluku, Papua
Bali and Nusa Tenggara
Borneo
Export
Total Account Receivables Third
Parties
Allowance for Impairment
Account Receivables Third
Parties - Net
Total
4.
Rupiah
Mata Uang Asing
Jumlah
31/ 12 / 2013
31 / 12 / 2012
445.156.290.980
443.996.278.531
112.687.069.087
33.283.191.650
557.843.360.067
(11.266.936.112)
546.576.423.955
477.279.470.181
(18.550.954.932)
458.728.515.249
IDR
Foreign Currency
Belum
Jatuh Tempo /
Not yet Due
1 Sampai
dengan 30 hari /
1-30 Days
Lebih
Dari 150 hari /
Over 150 Days
Jumlah
Total
BU M N
Instansi
Pemerintah
25.404.291.486
17.011.805.853
8.800.402.806
6.454.613.204
3.892.910.956
61.564.024.305
82.738.100.227
33.542.440.166
38.620.892.856
29.758.370.987
10.798.441.780
195.458.246.016
State-Owned
Enterprises
Government
Institution
Swasta
Ekspor
96.844.603.298
88.626.448.159
34.155.451.384
16.381.410.510
21.735.919.549
2.657.326.937
10.265.013.459
3.468.093.508
25.133.032.970
1.553.789.972
188.134.020.660
112.687.069.086
Private
Export
293.613.443.170
101.091.107.913
71.814.542.148
49.946.091.158
41.378.175.678
557.843.360.067
Jumlah
Penyisihan
kerugian
penurunan nilai
Jumlah
(11.266.936.112)
293.613.443.170
101.091.107.913
71.814.542.148
49.946.091.158
41.378.175.678
546.576.423.955
Total
Allowance
For
impairment
Total
40
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
155
4.
1 Sampai
dengan 30 hari /
1-30 Days
Lebih
Dari 150 hari /
Over 150 Days
Jumlah
Total
BU M N
Instansi
Pemerintah
25.176.655.127
19.031.093.797
4.379.215.304
47.968.395.273
7.520.492.877
104.075.852.378
75.839.527.519
58.655.757.665
17.067.944.914
18.670.007.015
8.987.814.709
179.221.051.822
State-Owned
Enterprises
Government
Institution
Swasta
Ekspor
74.987.102.369
16.598.440.812
37.868.063.202
8.758.355.915
6.919.059.820
7.926.394.923
6.133.081.111
-
34.792.067.829
-
160.699.374.331
33.283.191.650
Private
Export
192.601.725.827
124.313.270.579
36.292.614.961
72.771.483.399
51.300.375.415
477.279.470.181
Jumlah
Penyisihan
kerugian
penurunan nilai
Jumlah
(18.550.954.932)
192.601.725.827
124.313.270.579
36.292.614.961
72.771.483.399
51.300.375.415
458.728.515.249
31/ 12 / 2013
31 / 12 / 2012
18.550.954.932
1.151.869.603
(8.435.888.423)
11.266.936.112
18.912.012.918
829.596.168
(1.190.654.154)
18.550.954.932
5.
OTHER RECEIVABLES
31 / 12 / 2012
2.684.603.073
1.460.894.370
938.172.375
-
3.237.519.575
65.943.750
877.921.921
2.662.522.508
1.623.149.331
7.746.192.326
(101.635.938)
7.644.556.388
5.804.534.577
(66.142.346)
5.738.392.231
41
156
Beginning balance
Allowance for impairment
Recovered
Ending balance
31/ 12 / 2013
Piutang Pegawai
Jasa maklon
PT Indofarma Tbk
Listing fee
Lain-lain (di bawah
Rp1.000.000.000)
Jumlah
Penyisihan kerugian penurunan nilai
Jmlah
Total
Allowance
For
impairment
Total
Employees
Tolling
PT Indofarma Tbk
Listing fee
Others (bellows
Rp 1,000,000,000)
Total
Allowance for Impairment
Total
5.
31/ 12 / 2013
31 / 12 / 2012
66.142.346
35.493.592
101.635.938
Penyisihan
Pemulihan
INVENTORIES
31 / 12 / 2012
495.698.675.085
13.899.150.606
409.032.844.496
13.212.113.396
106.113.424.106
36.387.520.542
6.982.664.451
659.081.434.790
73.083.727.800
42.863.087.279
8.698.408.395
546.890.181.366
(18.172.074.618)
640.909.360.172
(16.472.881.709)
530.417.299.657
31 / 12 / 2013
Barang jadi /
Bahan Baku /
Finished goods
Raw materials
Saldo Awal Periode
Beginning Balance
Allowance (Recover) of Impairment
Ending Balance
6.
Barang jadi:
Obat jadi dan alat kontrasepsi
Alat kesehatan
144.066.990
(77.924.644)
66.142.346
Finished goods
Medicine and contraceptives
Medical equipment
Raw materials and indirect
materials
Work in process
Goods in transit
Allowance for inventories
obsolescence
Total
31 / 12 / 2012
Barang jadi /
Bahan Baku /
Finished goods
Raw materials
15.477.417.986
995.463.723
18.239.717.453
2.105.405.421
Beginning balance
6.683.634.446
685.271.902
7.171.347.797
582.731.845
Allowances
995.463.723
Ending balance
(5.561.628.585)
16.599.423.847
(108.084.854)
(9.933.647.264)
1.572.650.771
15.477.417.986
(1.692.673.543)
Recovered
42
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
157
6. PERSEDIAAN (Lanjutan)
6.
INVENTORIES (Continued)
7. UANG MUKA
7.
31/ 12 / 2013
31 / 12 / 2012
470.444.679
1.335.516.047
1.805.960.726
3.287.214.310
1.323.195.601
4.610.409.911
8. PERPAJAKAN
8.
TAXATION
a. Prepaid tax
31/ 12 / 2013
31 / 12 / 2012
147.793.961.008
2.130.209.622
146.370.791.527
2.054.506.841
12.421.519.454
14.618.907.167
5.272.943.098
1.498.878.305
961.143.025
184.697.561.679
5.272.943.098
10.769.360.920
1.171.036.969
733.207.842
165.200.810.228
43
158
ADVANCE PAYMENT
8. PERPAJAKAN (Lanjutan)
8.
TAXATION (Continued)
a. Prepaid tax (Continued)
b. Utang Pajak
b. Tax Payable
31/ 12 / 2013
PPh Pasal 25
PPh Pasal 23
31 / 12 / 2012
7.252.306.605
23.443.058.678
2.443.520.793
7.785.570.648
8.687.630.060
3.277.027.198
2.442.687.074
1.338.996.507
1.243.902.135
26.231.369.079
6.823.383.902
52.708.653.939
1.736.927.774
6.610.601.360
46.608.327.874
44
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
159
8. PERPAJAKAN (Lanjutan)
8.
TAXATION (Continued)
c. Estimated Income Taxes
31/ 12 / 2012
31 / 12 / 2011
Entitas Induk
Pajak kini
Pajak tangguhan
Sub jumlah
32.936.263.750
(2.348.177.809)
30.588.085.941
47.830.656.250
(150.554.857)
47.680.101.393
Parent
Current tax
Deferred tax
Sub total
Entitas Anak
Pajak kini
Pajak tangguhan
Sub jumlah
Jumlah
36.474.212.396
1.420.803.985
37.895.016.381
68.483.102.322
27.049.966.719
(2.209.613.435)
24.840.353.284
72.520.454.677
Subsidiaries
Current tax
Deferred tax
Sub total
Total
31/ 12 / 2013
31 / 12 / 2012
284.125.432.299
278.284.452.055
(138.189.061.705)
(80.103.569.874)
(9.967.908.032)
(4.722.701.182)
135.968.462.562
193.458.180.999
9.791.097.543
2.913.843.026
(470.679.165)
(63.272.161)
(129.898.780)
(132.420.868)
577.187.048
(1.109.941.698)
(283.390.922)
(125.243.543)
(152.110.355)
(796.976.042)
(6.120.751)
9.392.711.237
(17.142.668)
602.219.427
45
160
8. PERPAJAKAN (Lanjutan)
8.
TAXATION (Continued)
d. Corporate Income Tax (Continued)
31/ 12 / 2013
31 / 12 / 2012
5.995.022.276
4.245.289.864
4.313.187.690
-
4.535.803.056
853.170.471
(10.882.070.380)
(3.199.031.999)
(10.691.721.013)
(8.338.572.502)
(2.350.536.983)
(13.616.118.410)
131.745.055.389
(834.434.397)
(2.737.775.507)
191.322.624.919
131.745.055.000
191.322.625.000
Permanent differences
Calculated according to fiscal
Employee benefits
Representation, entertainment and
donation expenses
Adjustment from taxes assessment
Gain on sale of property already
subject to final tax
Rent income already subject to final
tax
Interest income already subject to
final tax
Total
Estimated taxable income tax
Estimated taxable income tax
(rounding)
Current tax expense
2013 : 25% X Rp 131,745,055,000
and
2012 : 25% X Rp191,322,625,000
32.936.263.750
32.936.263.750
47.830.656.250
47.830.656.250
131.745.055.000
145.896.849.584
277.641.904.584
191.322.625.000
108.199.866.876
299.522.491.876
32.936.263.750
36.474.212.396
69.410.476.146
47.830.656.250
27.049.966.719
74.880.622.969
6.033.456.826
39.324.326.378
45.357.783.204
3.600.432.584
20.787.164.988
24.387.597.572
33.978.391.741
88.118.458
11.273.181.064
45.339.691.263
19.090.578.666
88.735.626
12.686.166.650
31.865.480.942
(28.539.304.926)
(28.539.304.926)
(7.259.035.016)
(7.259.035.016)
7.252.306.605
7.252.306.605
23.443.058.678
2.443.520.793
25.886.579.471
46
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
161
8. PERPAJAKAN (Lanjutan)
8.
31 / 12 / 2012
2.447.774.385
728.460.757
144.296.762
(277.485.425)
(70.847.730)
(53.845.629)
(31.310.886)
(232.349.227)
(117.669.791)
(1.530.188)
2.348.177.809
(32.474.695)
(4.285.667)
150.554.857
521.828.507
3.401.473.501
280.501.465
(690.574.867)
(464.918.925)
(1.758.215.032)
(1.420.803.985)
927.373.824
(52.767.508)
(75.846.109)
(372.671.582)
2.209.613.435
2.360.168.292
Entitas Anak
Manfaat karyawan
Penyisihan persediaan usang
Penyusutan aset tetap
Penyisihan piutang usaha
Kompensasi rugi fiskal
Sub jumlah
Aset pajak tangguhan
31 / 12 / 2012
Subsidiaries
Employee benefits
Allowance for inventories
obsolescence
Depreciation of fixed assets
Provision for impairment
Fiscal compensation
Sub total
Deferred tax assets
3.278.403.700
9.314.703.564
3.332.249.328
6.866.929.179
994.652.250
1.112.322.039
92.442.479
163.290.166
393.162.700
248.865.931
(226.005.664)
(224.475.477)
18.901.125.356
2.759.146.016
18.379.296.834
4.517.361.048
4.149.855.962
3.869.354.496
(374.167.987)
90.751.008
Subsidiaries
Employee benefits
Provision for impairment
Provision for inventories
obsolescence
Depreciation of fixed assets
39.283.318.376
38.355.944.552
47
162
31/ 12 / 2013
TAXATION (Continued)
8. PERPAJAKAN (Lanjutan)
8.
31/ 12 / 2013
Laba sebelum pajak
per laporan keuangan konsolidasi
Beban pajak berdasarkan tarif pajak
Efek pajak dari beda tetap
Laba belum terealisasi
Beban pajak per laporan laba rugi
konsolidasi
TAXATION (Continued)
31 / 12 / 2012
Income before tax as consolidated
financial statements
Tax expenses based on tariff
Tax effect from permanent differences
Unrealized gain
Tax expense as
consolidated income statements
284.125.432.299
278.284.452.055
71.031.358.075
(56.278.745)
(2.491.977.008)
69.571.113.014
4.130.016.959
(1.180.675.296)
68.483.102.322
72.520.454.677
Entitas Induk
Pajak kini
Pajak tangguhan
Sub jumlah
32.936.263.750
(2.348.177.809)
30.588.085.941
47.830.656.250
(150.554.857)
47.680.101.393
Parent
Current tax
Deferred tax
Sub total
Entitas Anak
Pajak kini
Pajak tangguhan
Sub jumlah
Jumlah
36.474.212.396
1.420.803.985
37.895.016.381
68.483.102.322
27.049.966.719
(2.209.613.435)
24.840.353.284
72.520.454.677
Subsidiaries
Current tax
Deferred tax
Sub total
Total
31/ 12 / 2013
Kontrak Gedung dan Rumah Dinas
Kerja sama operasi dan ikatan kerja
sama
Premi asuransi
Lain-lain (di bawah
Rp1.000.000.000)
Jumlah
PREPAID EXPENSES
31 / 12 / 2012
26.505.802.851
18.883.538.525
4.664.261.392
2.866.498.503
2.938.942.317
803.125.437
794.279.039
34.830.841.785
1.979.485.803
24.605.092.082
48
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
163
31/ 12 / 2013
PT Husada Citra Medika
Pinjaman Pegawai
Penyisihan kerugian penurunan nilai
Jumlah
31 / 12 / 2012
510.056.116
51.101.711
561.157.827
(37.781.934)
523.375.893
1.117.056.116
130.332.070
1.247.388.186
(105.507.757)
1.141.880.429
Manajemen berpendapat bahwa penyisihan piutang raguragu adalah cukup untuk menutupi kemungkinan kerugian
dari piutang lain-lain.
Tahun 2012
Tahun 2013
Uraian
/ Explaination
Jumlah lembar
Saham yang dimiliki /
Shares Owned
Persentase
Kepemilikan /
Percentage Owned
450.000
30,00%
300.000
20,00%
921.912.000
(90.000)
210.000
30,00%
(279.559.623)
642.352.377
(261.374.648)
380.977.729
49
164
Ekuivalen
Rupiah /
Equivalent to
50
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
165
166
4.736.322.224
8.101.437.696
103.051.217.114
107.570.296.768
112.786.237.768
52.845.731.174
6.389.254.238
2.709.683.471
4.107.104.129
10.659.177.288
400.118.701.950
449.140.317.883
Kendaraan
Instalasi Limbah
Tanaman Menghasilkan
Aset Sewa Pembiayaan :
Kendaraan
Jumlah
Nilai Buku
22.461.377.981
92.760.968.382
1.263.848.181
70.522.796.541
29.190.002.306
849.259.019.833
24.488.038.643
820.069.017.527
657.060.425
11.050.000
2.831.592.189
Instalasi Limbah
1.192.001.232
133.654.910
6.692.548.888
Tanaman Menghasilkan
(4.303.124.941)
3.145.174.090
58.362.887.230
Kendaraan
(675.108.512)
51
(2.327.278.048)
(8.768.043.042)
(4.300.828.922)
(117.867.221)
(675.108.493)
(1.346.960.358)
(6.130.568.973)
(21.285.075.161)
(7.363.460.994)
(15.154.506.188)
(268.867.237)
7.895.068.252
18.007.536.953
140.001.598.738
(1.060.864.104)
135.558.958.900
10.948.769.029
185.300.306.111
(1.483.080.400)
28.460.634.701
12.
(121.331.046)
-
121.331.046
(27.689.254.956)
-
(368.488.080)
27.689.254.956
276.911.656
(276.911.656)
844.169.898
3.073.270.000
18.520.825.957
3.917.344.181
1.702.133.000
10.680.075.484
422.313.741.061
498.644.378.133
4.230.439.893
2.738.122.162
6.483.609.350
50.858.694.929
122.033.894.201
115.483.210.590
109.805.694.452
17.831.556.358
920.958.119.194
18.019.937.750
903.126.562.836
1.572.150.001
5.013.233.880
2.842.642.189
6.826.203.798
58.049.106.277
156.370.898.616
165.742.384.435
199.105.555.217
289.584.450.673
Saldo Akhir /
Ending Balance
FIXED ASSETS
Productive plant
Lease assets
Vehicles
Total
Book value
Vehicles
Construction in progress
Total
Accumulated Depreciation
Productive plant
Unproductive plant
Lease assets
Vehicles
Sub total
Vehicles
Land
Acquisition cost
260.904.763.372
Saldo Awal /
Beginning balance
Tanah
Harga Perolehan
167
(77.300.000)
(877.422.305)
-
9.343.000.337
1.186.123.727
40.750.000
-
121.515.927.136
57.831.499.608
6.651.798.888
2.831.592.189
4.437.707.995
Kendaraan
Instalasi Limbah
Tanaman Menghasilkan
(560.063.750)
(77.299.991)
(785.548.133)
-
24.788.981.886
12.192.044.586
2.642.776.439
88.646.811
40.636.224
52.078.623
4.330.823.121
57.268.810.452
83.341.378.632
100.671.493.173
50.909.594.365
6.300.607.427
2.669.047.247
4.055.025.506
8.265.524.215
346.246.409.636
426.719.769.958
Kendaraan
Instalasi Limbah
Tanaman Menghasilkan
Aset Sewa Pembiayaan :
Kendaraan
Jumlah
Nilai Buku
52
(1.858.261.542)
(3.396.518.135)
(115.344.719)
13.132.822.762
90.033.739.071
(33.193.930.532)
(38.745.856.573)
(3.335.623.800)
(5.551.926.041)
47.870.878.790
115.038.696.813
5.254.865.294
67.167.818.023
35.538.711.808
772.966.179.593
22.664.412.350
737.427.467.785
(748.783.880)
29.432.514.808
107.164.231.618
424.911.987
(190.578.055)
14.155.520.015
163.297.712.594
Tanah
1.065.703.474
(322.218.001)
12.
(78.908.503)
-
78.908.503
(21.025.657.760)
-
(95.615.201)
21.025.657.760
298.614.229
(298.614.229)
222.686.200
4.777.331.427
4.153.636.192
8.037.651.557
3.929.967.585
10.659.177.288
400.118.701.950
449.140.317.883
4.107.104.129
2.709.683.471
6.389.254.238
52.845.731.174
112.786.237.768
107.570.296.768
103.051.217.114
29.190.002.306
849.259.019.833
24.488.038.643
820.069.017.527
1.192.001.232
4.736.322.224
2.831.592.189
6.692.548.888
58.362.887.230
135.558.958.900
140.001.598.738
185.300.306.111
260.904.763.372
Saldo Akhir /
Ending Balance
FIXED ASSETS(Continued)
Productive plant
Lease assets
Vehicles
Total
Book value
Vehicles
Construction in progress
Total
Accumulated Depreciation
Unproductive plant
Lease assets
Vehicles
Sub total
Productive plant
Vehicles
Land
Acquisition cost
Saldo Awal /
Beginning balance
249.966.881.933
Harga Perolehan
31 / 12 / 2013
Harga pokok produksi:
Pertambangan
Manufaktur
Beban usaha:
Penelitian dan pengembangan
Umum dan administrasi
Jumlah
31 / 12 / 2012
298.894.593
12.464.511.223
310.365.762
10.292.053.116
451.907.096
17.747.769.242
30.963.082.154
372.840.129
19.721.230.122
30.696.489.129
Proyek s.d 31
Desember 2013
/ Project until
December 31,
2013
Nilai / Amount
100%
% Penyelesaian/
of completion
5.197.839.323
5.027.214.933
2.809.112.681
2.449.112.700
1.393.150.000
725.126.721
230.000.000
17.831.556.358
7.500.000.000
8.000.000.000
4.487.027.677
12.245.563.500
3.000.000.000
2.000.000.000
360.000.000.000
397.232.591.177
69%
83%
63%
20%
46%
36%
0,06%
53
168
Aset tetap tanah dengan HGB No. 5, No. 907, No. 275,
No. 2341, No. 139, No. 2671, No. 2770, No. 1889,
No. 285, No. 1226 dan No. 311 berikut bangunan di
atasnya semua atas nama Entitas digunakan sebagai
jaminan atas utang bank pada PT Bank Mandiri (Persero)
Tbk., PT Bank Central Asia Tbk. dan PT Bank Bukopin
Tbk. (lihat catatan.17).
Land with HGB No .5, No. 907, No. 275, No. 2341, No. 139,
No. 2671, No. 2770, No. 1889, No. 285, No. 1226 and
No. 311 including buildings are used as collateral to the
loans obtained from PT Bank Mandiri (Persero) Tbk.,
PT Bank Central Asia Tbk. and PT Bank Bukopin Tbk. (see
note 17).
1.196.984.146
151.000.016
2.296.019
1.350.280.181
17.347.125.443
448.000.016
795.371.491
18.590.496.950
16.150.141.297
297.000.000
793.075.472
17.240.216.769
397.451.337
188.720.139
1.569.236.430
2.155.407.906
4.012.910.808
197.670.948
1.883.822.138
6.094.403.894
3.615.459.471
8.950.809
314.585.708
3.938.995.988
54
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
169
31 / 12 / 2012
27.388.996.305
(26.757.240.094)
631.756.211
27.388.996.305
(26.569.295.672)
819.700.633
Biaya perolehan
Software komputer
Hak atas Tanah
31 / 12 / 2012
1.455.537.970
4.217.385.507
5.672.923.477
681.457.970
3.941.757.381
4.623.215.351
55
170
Acquisition cost
Computer software
Land right
(504.490.682)
(1.730.392.950)
(2.260.854.262)
3.412.069.215
(1.536.442.844)
(2.040.933.526)
2.582.281.825
Less :
Accumulated amortization of
computer software
Accumulated amortization of
land right
31 / 12 / 2012
90.927.629.977
56.438.019.499
18.043.676.664
175.883.157
109.147.189.798
11.243.452.344
380.597.319
223.206.139
68.285.275.301
Beginning balance
Penambahan /
Addition
Dipindahkan ke
Reklasifikasi /
Reclassification
Saldo akhir /
jangka pendek /
Ending Balance
Deffered expense
Biaya ditangguhkan
Cost
Biaya perolehan
Sewa jangka panjang
IKS/KSO
Sub jumlah
107.391.065.380
87.378.410.457
(24.821.641.764)
169.947.834.073
23.919.883.736
18.974.444.987
(4.664.261.392)
38.230.067.331
JO/JC
131.310.949.116
106.352.855.444
(29.485.901.112)
208.177.901.404
Sub total
Accumulated
Akumulasi amortisasi
Sewa jangka panjang
50.953.045.881
28.067.158.215
79.020.204.096
IKS/KSO
12.676.431.392
7.509.959.275
20.186.390.667
JO/JC
Sub jumlah
63.629.477.273
35.577.117.490
99.206.594.763
Sub total
Nilai Buku
67.681.471.843
108.971.306.641
Book value
56
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
171
Saldo awal /
Beginning balance
Penambahan /
Addition
Dipindahkan ke
Reklasifikasi /
Reclassification
Saldo akhir /
jangka pendek /
Ending Balance
Deffered expense
Biaya ditangguhkan
Cost
Biaya perolehan
Sewa jangka panjang
78.337.055.053
30.978.040.096
14.040.133.767
(15.964.163.536)
107.391.065.380
IKS/KSO
17.943.472.494
8.915.353.559
(2.938.942.317)
23.919.883.736
JO/JC
96.280.527.547
39.893.393.655
14.040.133.767
(18.903.103.810)
131.310.949.116
Sub jumlah
Sub total
Accumulated
Akumulasi amortisasi
Sewa jangka panjang
IKS/KSO
Sub jumlah
Nilai Buku
33.806.304.050
17.146.741.831
50.953.045.881
9.251.977.626
3.424.453.766
12.676.431.392
JO/JC
43.058.281.676
20.571.195.597
63.629.477.273
Sub total
67.681.471.843
Book value
53.222.245.871
31 / 12 / 2013
31 / 12 / 2012
28.067.158.215
2.527.268.587
17.146.741.831
1.321.241.384
4.982.690.688
35.577.117.490
2.103.212.382
20.571.195.597
Marketing expenses :
Amortization of rent expense
Amortization of JO
General expense
Amortization of JO
Total
57
172
31 / 12 / 2012
38.367.334.986
8.430.902.999
6.539.756.681
6.717.823.360
288.649.024
288.943.910
47.375.830.919
235.481.101
3.884.047.624
17.377.108.766
Related parties
PT Bank Mandiri (Persero) Tbk
IDR
USD 691,681.27 in 2013
Third Parties
PT Bank Bukopin Tbk.
PT Bank Central Asia Tbk
Total
6,25% - 13,50%
6,25% - 13,50%
58
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
173
Entitas memperoleh fasilitas kredit Uncommitted Demand Loan ( UDL) Umbrella Facility dari PT Bank
OCBC NISP, Tbk sebesar Rp 50.000.000.000 untuk
tujuan modal kerja untuk membiayai persediaan,
piutang, dan pengeluaran umum, tanggal akhir
penyedian Demand Loan pada tanggal 13 Mei 2013,
pada tanggal 12 Agustus 2013 fasilitas kredit ini
diperpanjang sampai dengan tanggal 13 Mei 2014, atas
atas fasilitas kredit ini tidak ada jaminan (Negative
pledge). Saldo pinjaman entitas per 31 Desember 2013
dan 2012 bersaldo nihil.
59
174
The loan has been extended until September 23, 2013 and to
amend the credit facility from flats to revolving, with
lending rates of 12.5% for the three (3) months of the first
and will then be reviewed. The outstanding loan
subsidiaries as of December 31, 2013, and 2012 amounted
to Rp 288,649,024 and Rp 3,884,047,624.
60
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
175
Entity loan balances per December 31, 2013 and 2012 was
nil, interest rate is the cost of financing (cost of funds) plus
1.5% per year. Warranty documents (warranties and
warranty documents), fees and insurance are not required.
61
176
is
in
of
in
PT Novapherin
PT Narda Tita
PT United Dico Citas
CV Mutiara
PT Erela
PT Marlin Lisa Farma
PT Combi Putra
PT Tatarasa Primatama
PT Tiga Anugrah
PT Pasific Rimutama
PT Indochemicals Citra Kimia
PT Tigaka Distrindo Perkasa
PT Reckit Benckiser Indonesia
31 / 12 / 2012
17.030.539.918
1.941.691.808
833.213.957
253.482.309
1.662.931.371
21.721.859.363
17.119.128.416
1.520.239.030
6.440.802.158
10.456.599.586
1.347.607.842
36.884.377.032
52.729.271.400
50.820.148.554
26.019.206.995
22.821.879.107
19.860.751.720
18.002.823.007
16.129.317.513
12.368.308.409
10.511.385.939
9.891.311.647
9.866.949.456
9.182.014.306
7.852.033.808
7.782.223.492
6.194.627.495
6.126.834.596
4.880.725.689
4.532.638.156
3.991.245.448
3.297.688.640
2.713.537.970
2.516.917.919
2.131.730.026
1.938.383.132
1.635.708.346
1.504.240.802
1.446.406.861
1.344.769.599
1.341.456.817
1.237.821.361
1.140.016.800
1.046.303.760
835.898.444
-
3.254.815.392
3.164.020.059
22.710.618.535
19.268.645.287
21.394.377.853
11.647.890.460
11.843.400.274
7.014.814.454
8.654.650.199
8.856.788.568
6.128.791.606
7.662.542.256
6.333.302.702
5.172.608.924
4.945.168.589
4.774.006.438
2.957.086.513
4.172.904.303
3.015.462.390
3.861.826.680
1.623.575.060
2.174.051.934
973.693.515
368.756.856
1.431.742.250
1.203.154.128
323.328.319
763.682.232
728.412.754
1.970.683.715
5.054.559.122
Related Parties
PT Perkebunan Nusantara VIII
PT Bio Farma (Persero)
PT Rajawali Nusindo
PT Indo Farma Global Medika
Lain-lain
Total
Third Parties
PT Gratia Jaya Mulia
PT Jonhson & Johnson Indonesia
PT Anugrah Parmindo Lestari
PT Arnold Suhr
PT Anugerah Argon Medika
PT Enseval Putra Megatrading
PT Merapi Utama Farma
PT Parit Padang Global
PT Masarinda abadi
PT Dos Ni Roha
PT Bina San Prima
PT Mensa Bina Sukses
PT Antar Mitra Sembada
World Botanical s Product
PT Tempo
PT Milenium Pharmacon
PT Kalista
PT Daya Muda Agung
PT Penta Valent
PT Kebayoran Farma
PT Avesta Continental Packing
PT Novapherin
PT Narda Tita
PT United Dico Citas
CV Mutiara
PT Erela
PT Marlin Lisa Farma
PT Combi Putra
PT Tatarasa Primatama
PT Tiga Anugrah
PT Pasific Rimutama
PT Indochemicals Citra Kimia
PT Tigaka Distrindo Perkasa
PT Reckit Benckiser Indonesia
62
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
177
31 / 12 / 2012
806.617.254
483.420.304
198.482.557
-
1.090.123.908
1.260.590.660
1.172.625.766
1.194.359.497
130.986.794.618
456.169.891.947
477.891.751.310
116.081.599.317
304.248.660.515
341.133.037.547
31 / 12 / 2013
Belum jatuh tempo
1 sampai dengan 30 hari
31 sampai dengan 60 hari
61 sampai dengan 150 hari
Lebih dari 150 hari
Jumlah
31 / 12 / 2012
314.385.479.485
131.054.168.701
20.500.418.202
4.965.645.427
6.986.039.495
477.891.751.310
217.496.968.636
69.722.186.424
29.816.549.460
13.524.343.442
10.572.989.585
341.133.037.547
31 / 12 / 2013
31 / 12 / 2012
Rupiah
Mata uang asing
USD 3.206.152,18 :
31 Desember 2013 dan
USD 1.683.382,62 :
31 Desember 2012
EUR 7.154,67 : 31 Desember 2013
dan
EUR 15.288,00 : 31 Desember 2012.
438.691.610.048
324.658.890.508
39.079.788.933
16.278.309.899
120.352.329
195.837.140
Jumlah
477.891.751.310
341.133.037.547
63
178
IDR
Foreign currency
USD 3,206,152.18:
December 31, 2013 and
USD 1,683,382.62:
December 31, 2012
EUR 7,154.67:
December 31, 2010 and
EUR 15,288.00:
January 1, 2010
Total
31 / 12 / 2013
Gaji dan kesejahteraan karyawan
Promosi dan beban penjualan
Tantiem direksi dan
komisaris
Biaya pemeliharaan
Biaya pabrikasi
Biaya Listrik, gas, air dan
bahan bakar
Biaya bunga bank
Lain-lain (di bawah Rp1.000.000.000)
Jumlah
31 / 12 / 2012
69.142.370.970
30.512.250.120
47.586.573.723
32.567.300.353
8.598.000.000
4.038.659.565
2.874.345.838
6.171.935.000
1.317.073.301
1.968.283.318
1.466.648.568
144.444.444
1.184.735.944
117.961.455.449
827.380.164
792.506.403
91.281.052.262
31 / 12 / 2012
4.537.277.699
13.703.705.516
(928.504.902)
3.608.772.797
(3.227.046.798)
10.476.658.718
(1.735.823.535)
1.872.949.262
(4.086.850.879)
6.389.807.839
64
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
179
PT Jitu
Koperasi Mandiri
PT Saseka Gelora
PT Astrindo Finance
PT BII Finance
PT Toyota Astra Finance
PT Adira Finance
Koperasi Bina Asih
Tunas Toyota
Koperasi Yodium Farma
Jumlah
22. LIABILITAS LANCAR LAINNYA
31 / 12 / 2012
12.794.909.089
10.342.249.171
6.647.897.611
4.014.471.568
3.206.833.574
1.461.702.618
1.079.271.050
13.090.909.088
7.875.205.689
3.310.947.637
3.225.320.516
255.238.005
-
3.308.619.498
6.824.654.825
46.371.989.506
3.966.331.655
35.032.572.088
Jansen Indonesia
PT Tirta Investama
Dividend
Koperasi Chincona
PT Cipta Kreasindo
Partnership and community
development program
Others (below
Rp 1,000,000,000)
Total
31 / 12 / 2012
35.290.504.450
27.805.856.843
64.298.257.643
99.588.762.093
63.433.991.211
91.239.848.054
65
180
Unearned revenue of
rent buildings
Acquisitions fixed assets
PT Jitu
Koperasi Mandiri
PT Saseka Gelora
PT Astrindo Finance
PT BII Finance
PT Toyota Astra Finance
PT Adira Finance
Koperasi Bina Asih
Tunas Toyota
Koperasi Yodium Farma
Jumlah
31 / 12 / 2013
Biaya jasa kini Entitas
Beban bunga
Amortisasi biaya jasa lalu
Amortisasi kerugian aktuaria
Dampak perubahan asumsi
atuaria
Iuran dana pensiun/premi asuransi
Beban (hasil) aset bersih
Jumlah
31 / 12 / 2012
3.438.861.442
20.588.088.698
147.471.174
21.763.238.421
3.035.213.432
19.660.537.022
147.471.174
3.891.107.965
13.234.093.127
(38.075.303.680)
(13.611.801.575)
7.484.647.607
22.702.532.515
(23.730.179.931)
(12.863.169.612)
12.843.512.565
31 / 12 / 2013
Nilai kini kewajiban pada
akhir periode
Nilai wajar aset akhir periode
Status pendanaan
Biaya jasa lalu yang belum diakui
Kerugian aktuaria yang belum diakui
Aset manfaat pensiun karyawan
31 / 12 / 2012
281.714.552.780
257.351.108.722
(188.443.225.875)
93.271.326.905
(170.147.519.690)
87.203.589.032
837.837.405
(58.818.659.860)
35.290.504.450
690.366.230
(60.088.098.419)
27.805.856.843
66
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
181
31 / 12 / 2013
Saldo awal tahun
Beban (manfaat) pensiun karyawan
bersih
Saldo akhir tahun
31 / 12 / 2012
27.805.856.843
14.962.344.278
7.484.647.607
35.290.504.450
12.843.512.565
27.805.856.843
Beginning balances
Net employee pension expenses
(return)
Ending balance
10 tahun/years
55 tahun/years
45 tahun/years
67
182
Manager
Asisten Manajer
Supervisor
Pelaksana
Level
Manager
Manager Assistant
Supervisor
Executive Officer
31 / 12 / 2013
Beban jasa kini
Beban bunga
Amortisasi kewajiban aktuaria yang
belum diakui
Amortisasi keuntungan aktuaria
Jumlah beban manfaat imbalan kerja
karyawan bersih
31 / 12 / 2012
7.797.069.488
11.112.722.598
5.713.211.491
9.981.409.752
105.497.426
5.913.622.948
534.066.140
4.214.399.394
24.928.912.460
20.443.086.777
31 / 12 / 2013
Nilai sekarang kewajiban imbalan
kerja
Biaya jasa lalu yang belum
diakui
Keuntungan (kerugian) aktuaria yang
belum diakui
Saldo akhir di neraca
31 / 12 / 2012
177.456.214.489
141.627.861.117
(922.536.697)
(1.028.034.123)
(112.235.420.150)
64.298.257.642
(77.165.835.783)
63.433.991.211
68
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
183
31 / 12 / 2013
Saldo awal tahun
Beban imbalan kerja yang diakui
pada tahun berjalan
Pembayaran imbalan kerja selama
periode berjalan
Saldo akhir tahun
63.433.991.211
63.563.176.748
24.928.912.460
20.443.086.777
(24.064.646.029)
64.298.257.642
(20.572.272.314)
63.433.991.211
%
Penyertaan/
Investment
44,00%
00,04%
00,00%
Jumlah / Total
%
Penyertaan/
Investment
Jumlah / Total
44,00%
00,04%
00,00%
7.290.000.000
5.000.000
100
7.743.763.701
(1.896.316)
100
1.092.522.652
653.028
37
16.126.286.353
3.756.712
237
7.295.000.100
7.741.867.485
1.093.175.717
16.130.043.302
Saham/
Shares
7.290.000.000
5.000.000
100
7.113.083.602
(1.896.938)
78
630.680.099
622
22
15.033.763.701
3.103.684
200
7.295.000.100
7.111.186.745
630.680.743
15.036.867.585
69
184
10 tahun/years
55 tahun/years
45 tahun/years
31 / 12 / 2012
Penyertaan /
Harga Perolehan /
Nilai Wajar /
Selisih /
Investment
Acquisition Value
Fair Value
Difference
56,00%
18.578.965.212
28.663.607.062
10.084.641.850
18.578.965.212
28.663.607.062
10.084.641.850
%
Kepemilikan /
Ownership
Jumlah /
Total
1
4.999.999.999
0,01
90,02
100
499.999.999.900
553.875.000
9,97
55.387.500.000
82.500
42.500
5.554.000.000
8.250.000
4.250.000
100.00
555.400.000.000
1. Government of
Republic of Indonesia
- Series A
Dwiwarnashares
- Series B shares
2. General
- Series B shares
3. Management Series B
Shares
- Jisman Siagian
- Pujianto
Total issued and paid
shares
%
Kepemilikan /
Ownership
Jumlah /
Total
1
4.999.999.999
0,01
90,02
100
499.999.999.900
553.875.000
9,97
55.387.500.000
82.500
42.500
5.554.000.000
8.250.000
4.250.000
100.00
555.400.000.000
1. Government of
Republic of Indonesia
- Series A
Dwiwarnashares
- Series B shares
2. General
- Series B shares
3. Management Series B
Shares
- Jisman Siagian
- Pujianto
Total issued and paid
shares
70
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
185
100.000.000.000
9.720.000.000
(55.400.000.000)
54.320.000.000
(10.740.379.969)
43.579.620.031
28. PENJUALAN
Penjualan Ekspor:
Garam Kina
31 / 12 / 2012
3.837.162.456.860
3.292.700.937.548
307.953.869.355
106.774.212.376
21.962.846.000
74.220.603.794
4.348.073.988.385
Obat Generik
Obat Ethical, Lisensi dan
Narkotika
Local sales:
Third parties
296.345.233.222
Related parties
103.447.906.039
Quinine salt
27.389.088.000
14.357.936.500
3.734.241.101.309
28. SALES
31 / 12 / 2013
Penjualan Lokal:
31 / 12 / 2013
31 / 12 / 2012
372.632.965.597
403.269.617.359
509.676.232.098
558.286.950.022
157.489.725.001
258.115.289.715
141.993.011.911
10.630.158.899
1.192.422.093.506
163.273.152.509
11.273.652.109
1.394.218.661.714
1.816.741.567.698
664.886.034.468
497.992.608.091
176.031.684.622
3.155.651.894.879
4.348.073.988.385
1.564.923.345.645
509.955.839.089
130.266.680.388
134.876.574.473
2.340.022.439.595
3.734.241.101.309
71
186
For the year ended December 31, 2013 and 2012, sales
over 10 % from total net sales.
29. COST OF GOODS SOLD
31 / 12 / 2013
Pertambangan
Biaya Produksi
Biaya tak langsung
Pemakaian bahan
Biaya langsung
Sub jumlah
Produksi manufaktur
Pemakaian bahan
Biaya langsung
Biaya pabrikasi:
Gaji dan kesejahteraan
karyawan
BBM, listrik, air, gas & bahan
kimia
Pemeliharaan dan peralatan
Penyusutan
Lain-lain (di bawah
Rp1.000.000.000)
Barang dalam proses
Awal periode
Akhir periode
Sub jumlah produksi
manufaktur
Jumlah biaya produksi manufaktur dan
pertambangan
Barang Jadi
Awal periode
Pembelian
Akhir periode
Sub jumlah
Jumlah
31 / 12 / 2012
Mining
Production Cost
Indirect cost
Raw materials used
Direct cost
Sub Total
2.250.548.624
2.456.373.600
9.399.048.427
14.105.970.651
2.303.563.950
2.032.956.334
10.472.476.226
14.808.996.510
367.196.732.573
54.987.221.733
333.755.205.584
52.427.647.520
85.296.690.047
74.983.927.599
23.722.388.807
21.487.777.795
12.464.511.223
18.991.443.060
20.733.475.893
10.292.053.116
8.366.145.374
151.337.513.246
7.205.331.223
518.389.083.995
42.863.087.279
(36.387.520.542)
41.210.981.190
(42.863.087.279)
579.997.034.289
516.736.977.906
Work in Process
Beginning balances
Ending balances
Sub total manufacturing
production
594.103.004.940
531.545.974.416
399.484.725.831
2.050.288.388.019
(422.244.957.895)
2.027.528.155.951
2.559.074.130.367
Finished goods
Beginning balances
Purchasing
Ending balances
Sub total
Total
422.244.957.892
2.549.171.809.853
(509.597.825.691)
3.041.815.976.343
3.055.921.946.994
Manufacturing Production
Raw materials used
Direct cost
Manufacturing expenses:
Salaries and
employee's welfare
Fuel, electricity, water,
gas and chemicals
Maintenance and equipment
Depreciation
Others
(below Rp1,000,000,000)
72
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
187
31 / 12 / 2012
Selling Expense
380.154.895.357
106.408.142.010
50.257.773.448
326.673.279.267
99.123.276.917
52.366.662.990
64.028.531.090
12.140.612.272
50.252.431.980
9.836.070.008
3.839.266.826
1.234.734.456
616.829.221.003
539.486.455.618
31 / 12 / 2013
31 / 12 / 2012
162.244.748.315
33.855.794.000
24.775.350.899
25.989.635.591
18.376.294.558
17.921.890.132
8.598.000.000
6.171.935.000
17.747.769.242
Office travelling
19.721.230.122
15.194.594.607
15.705.361.410
17.253.993.473
14.785.718.859
16.949.351.678
12.879.516.839
6.683.634.446
7.754.079.642
Jasa profesional
7.732.181.744
8.211.006.658
12.578.925.967
73
188
22.620.877.461
29.258.288.601
Others
(below Rp1,000,000,000)
Total
127.524.986.596
32.846.155.193
33.086.010.384
Asuransi
5.174.540.414
6.762.482.504
5.079.877.868
1.675.691.742
7.484.647.606
4.674.102.063
12.843.512.565
1.119.637.372
829.596.168
18.328.172.804
13.575.701.932
425.789.665.752
1.042.618.886.755
373.112.958.757
912.599.414.375
31 / 12 / 2012
8.451.600.374
803.041.210
385.000.000
9.639.641.584
5.525.670.962
1.286.732.425
60.000.000
6.872.403.387
Insurance
Continued
of
to
31 / 12 / 2012
17.240.216.769
7.193.521.298
4.182.762.174
3.994.842.962
2.591.144.248
2.247.760.758
1.740.181.131
1.112.263.082
3.379.025.843
43.681.718.265
3.938.995.988
5.999.108.714
3.376.787.086
4.168.500.890
2.361.514.614
1.772.510.209
1.230.562.109
192.396.712
31.450.382
1.063.584.383
24.135.411.087
74
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
189
Laba Bersih
Net Incomes
Jumlah Saham
Number of Shares
Earnings per share for the years ended December 31, 2013
and 2012 amounting to Rp 38.63
and Rp 36.93
respectively.
Dividen
Cadangan Umum
31 / 12 / 2012
30.769.997.495
34.353.197.492
Dividend
172.311.985.973
130.541.770.468
General reserves
tunai.
Dividend.
Lingkungan.
development program
laba.
75
190
tunai.
Dividend.
kemitraan.
program.
Lingkungan.
development program
Tahap / Step
7.731.611.787
II
5.798.708.840
III
5.798.708.840
IV
5.798.708.840
5.798.708.841
Jumlah / Total
36. TRANSAKSI DENGAN PIHAK-PIHAK BERELASI
Jumlah / Amount
(Rp)
30.926.447.148
36. RELATED PARTIES TRANSACTIONS
a.
a.
76
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
191
b.
b.
Entity put its fund and has loan funds on state owned
enterprise banks with requirements and normal
interest rate such as that apply to third parties
customers.
c.
c.
6
7
PT Jamsostek (Persero)
10
11
12
13
14
15
16
17
PT Taspen (Persero)
18
PT Pelabuhan Indonesia
19
20
Sifat hubungan
BUMN/ State
OwnedEnterprise
BUMN/ State
OwnedEnterprise
BUMN/ State
OwnedEnterprise
BUMN/ State
OwnedEnterprise
BUMN/ State
OwnedEnterprise
BUMN/ State
OwnedEnterprise
BUMN/ State
OwnedEnterprise
BUMN/ State
OwnedEnterprise
BUMN/ State
OwnedEnterprise
BUMN/ State
OwnedEnterprise
BUMN/ State
OwnedEnterprise
BUMN/ State
OwnedEnterprise
BUMN/ State
OwnedEnterprise
BUMN/ State
OwnedEnterprise
BUMN/ State
OwnedEnterprise
BUMN/ State
OwnedEnterprise
BUMN/ State
OwnedEnterprise
BUMN/ State
OwnedEnterprise
BUMN/ State
OwnedEnterprise
BUMN/ State
OwnedEnterprise
77
192
Transaksi
Penempatan dana di rekening bank dan penjualan
obat/Account bank and medicine sales
Penempatan dana di rekening bank, fasilitas
pinjaman daribank/ Account bank, loans bank
facilities
Penempatan dana di rekening bank/ Account bank
Penempatan dana di rekening bank/ Account bank
Penempatan dana di rekening bank/ Account bank
Penjualan Obat menggunakan kartu ASKES/
Medicinesales using ASKES card
Penjualan Obat/ Medicine sales
Penjualan Obat/ Medicine sales
Penjualan Obat/ Medicine sales
Penjualan Obat/ Medicine sales
Penjualan Obat/ Medicine sales
Penjualan Obat/ Medicine sales
Penjualan Obat/ Medicine sales
Penjualan Obat/ Medicine sales
Penjualan Obat/ Medicine sales
Penjualan Obat/ Medicine sales
Penjualan Obat/ Medicine sales
Penjualan Obat/ Medicine sales
Penjualan Obat/ Medicine sales
Penjualan Obat/ Medicine sales
21
PT Garam (Persero)
22
23
PT Rajawali Nusindo
Sifat hubungan
BUMN/ State
OwnedEnterprise
Entitas anak
BUMN / State
Owned Enterprise
Subsidiary
Entitas anak
BUMN / State
Owned Enterprise
Subsidiary
31 / 12 / 2013
Bank
Rupiah
PT Bank Mandiri (Persero) Tbk.
PT Bank Pembangunan
Daerah
PT Bank Rakyat Indonesia
(Persero) Tbk.
PT Bank Negara Indonesia
(Persero) Tbk.
PT Bank BRI Syariah
PT Bank Syariah Mandiri
Jumlah Bank Rupiah
Mata uang asing
Dolar
PT Bank Mandiri (Persero)
Tbk.
Jumlah Mata Uang Asing
Jumlah Bank
Persentase terhadap jumlah aset
Deposito
Rupiah
PT Bank Tabungan Negara
(Persero) Tbk
PT Bank Mandiri (Persero)
Tbk.
PT Bank Jabar Banten Tbk
Jumlah Deposito
Persentase terhadap jumlah aset
Transaksi
Pembelian Obat/ Medicine sales
Pembelian / Penjualan obat / Medicine purchase /
sales
Pembelian / Penjualan obat / Medicine purchase /
sales
31 / 12 / 2012
210.840.107.926
181.650.290.463
66.439.937.055
50.110.996.447
13.523.358.812
10.495.042.250
8.492.200.810
984.819.239
202.630.747
300.483.054.589
9.113.462.414
1.469.087.508
615.657.478
253.454.536.560
9.288.741.947
9.288.741.947
309.771.796.536
12,53%
5.702.154.788
5.702.154.788
259.156.691.348
12,48%
10.000.000.000
20.000.000.000
10.000.000.000
10.000.000.000
30.000.000.000
1,21%
20.000.000.000
0,96%
Bank
IDR
PT Bank Mandiri (Persero)Tbk.
PT Bank Pembangunan
Daerah
PT Bank Rakyat Indonesia
(Persero) Tbk.
PT Bank Negara Indonesia
(Persero) Tbk.
PT Bank BRI Syariah
PT Bank Syariah Mandiri
Total Bank IDR
Foreign Currency
USD
PT Bank Mandiri (Persero)
Tbk.
Total Foreign Currency
Total Bank
Percentage of total assets
Deposits
IDR
PT Bank Tabungan Negara
(Persero) Tbk
PT Bank Mandiri (Persero)
Tbk.
PT Bank Jawa Barat Tbk
Total Deposits
Percentage of total assets
78
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
193
31 / 12 / 2013
Piutang Usaha
31 / 12 / 2012
Perusahaan
(Persero)
Listrik
Negara
Perkebunan
(Persero)
Nusantara
IV
PT Jamsostek (Persero)
PT
Telekomunikasi
(Persero) Tbk.
PT
Tbk.
Aneka
Tambang
27.455.042.487
14.780.402.542
9.854.718.156
6.183.808.509
4.375.195.262
Indonesia
(Persero)
288.093.417
(Persero)
41.032.678.107
1.321.767.990
1.587.313.378
2.046.056.531
1.240.162.106
Indonesia (Persero)
2.235.420.928
1.965.492.208
1.322.356.643
PT Pertamina (Persero)
PT Timah (Persero)Tbk
PT Asuransi Kesehatan
3.178.489.873
PT Rajawali Nusindo
Account Receivables
934.193.360
1.102.982.690
1.184.569.513
975.804.967
1.365.583.048
PT Perkebunan Nusantara IV
PT Rajawali Nusindo
PT Jamsostek (Persero)
PT Pertamina (Persero)
PT Timah (Persero)Tbk
PT Telekomunikasi Indonesia
(Persero) Tbk.
PT Aneka Tambang (Persero)
Tbk.
452.270.594
19.966.713.468
Rp 1.000.000.000)
Jumlah
Penyisihan kerugian penurunan
nilai
8.319.741.328
61.564.024.304
12.460.426.192
104.065.258.993
Others (Below Rp
1,000,000,000)
Total
(29.876.495)
(294.769.822)
61.534.147.809
2,49%
103.770.489.171
4,99%
31 / 12 / 2013
Utang Bank
PT Bank Mandiri (Persero) Tbk.
Rupiah
USD
Jumlah
Persentase terhadap jumlah
liabilitas
31 / 12 / 2012
38.367.334.986
8.430.902.999
46.798.237.985
6.539.756.681
6.717.823.360
13.257.580.041
5,52%
2,09%
79
194
Bank Loans
PT Bank Mandiri (Persero) Tbk.
IDR
USD
Total
Percentage of total
liabilities
31 / 12 / 2013
Utang Usaha
PT Perkebunan Nusantara
VIII (Persero)
PT Bio Farma (Persero)
PT Rajawali Nusindo
PT Indo Farma Global Medika
Lain-lain (di bawah
Rp 1.000.000.000)
Jumlah
Persentase terhadap jumlah
liabilitas
31 / 12 / 2012
17.030.539.918
17.119.128.416
1.941.691.808
833.213.957
253.482.309
1.520.239.030
6.440.802.158
10.456.599.586
21.721.859.363
36.884.377.032
1.662.931.371
1.347.607.842
2,56%
5,81%
31 / 12 / 2013
Penjualan
PT Asuransi Kesehatan
Indonesia (Persero)
PT Perusahaan Listrik
Negara (Persero)
PT Angkasa Pura II (Persero)
PT Kawasan Berikat
Nusantara (Persero)
PT Jamsostek (Persero)
PT Aneka Tambang (Persero)
Tbk.
PT Telekomunikasi Indonesia
(Persero) Tbk.
PT Timah (Persero) Tbk
PT Pertamina (Persero)
PT Indo Farma Global
Medika
PT Rajawali Nusindo
PT Pos Indonesia (Persero)
PT Perkebunan Indonesia
(Persero) IV
PT Bio Farma (Persero)
PT Pelabuhan Indonesia
(Persero) II
PT Angkasa Pura (Persero) I
PT Perkebunan Indonesia
(Persero) II
PT Pelni (Persero)
Lain-lain (masing-masing dibawah
Rp1.000.000.000)
Jumlah
Persentase terhadap jumlah penjualan
Account Payables
PT Perkebunan Nusantara
VIII (Persero)
PT Bio Farma (Persero)
PT Rajawali Nusindo
PT Indo Farma Global Medika
Others (Below
Rp 1,000,000,000)
Total
Percentage of total
liabilities
31 / 12 / 2012
130.879.112.960
103.872.739.401
40.012.750.093
22.742.502.001
40.357.748.221
15.205.931.587
22.739.903.636
13.785.480.239
11.706.305.941
8.382.323.933
7.147.751.594
6.488.768.505
5.931.960.417
5.011.853.821
5.226.656.896
4.726.286.703
6.498.902.330
3.923.751.037
3.791.643.852
3.641.309.729
16.805.400.946
39.616.382.110
3.015.133.987
3.320.520.204
2.907.623.067
475.815.528
2.446.073.592
1.915.979.505
1.478.235.286
1.044.414.257
1.098.224.485
1.384.028.994
597.018.405
3.986.484.705
29.019.103.671
307.953.869.355
7,08%
33.114.980.939
296.345.233.222
7,94%
Sales
PT Asuransi Kesehatan
Indonesia (Persero)
PT Perusahaan Listrik
Negara (Persero)
PT Angkasa Pura II (Persero)
PT Kawasan Berikat
Nusantara (Persero)
PT Jamsostek (Persero)
PT Aneka Tambang (Persero)
Tbk.
PT Telekomunikasi Indonesia
(Persero) Tbk.
PT Timah (Persero) Tbk
PT Pertamina (Persero)
PT Indo Farma Global
Medika
PT Rajawali Nusindo
PT Pos Indonesia (Persero)
PT Perkebunan Indonesia
(Persero) IV
PT Bio Farma (Persero)
PT Pelabuhan Indonesia
(Persero) II
PT Angkasa Pura (Persero) I
PT Perkebunan Indonesia
(Persero) II
PT Pelni (Persero)
Others (Below
Rp 1,000,000,000)
Total
Percentage of total sales
80
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
195
31 / 12 / 2013
Pembelian
PT Bio Farma (Persero)
PT Rajawali Nusindo
PT Perkebunan Nusantara
VIII (Persero)
PT Indofarma Global Medika
Lain-lain (di bawah
Rp 1.000.000.000)
Jumlah
Persentase terhadap jumlah pembelian
31 / 12 / 2012
12.894.429.142
8.861.700.729
12.651.891.291
23.796.396.995
6.411.411.502
3.574.158.370
13.443.709.187
26.800.036.925
4.403.000.286
36.144.700.029
1,18%
3.229.344.963
79.921.379.361
3,12%
81
196
Purchases
PT Bio Farma (Persero)
PT Rajawali Nusindo
PT Perkebunan Nusantara
VIII (Persero)
PT Indofarma Global Medika
Others (Below
Rp 1,000,000,000)
Total
Percentage of total purchase
82
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
197
83
198
84
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
199
The Entity did not disclose the amount of sales and expenses
for each distribution and marketing agreement because the
Entitys main activities are distribution and marketing of
pharmaceutical products in addition to the manufacturing.
Informasi
segmen
Entitas
disajikan
menurut
pengelompokan kegiatan usaha yaitu, produksi, distribusi
dan apotek/ritel (unit usaha) dan berdasarkan geografis
dibagi dalam 5 (lima) wilayah yang terdiri dari:
Wilayah/ Region
Sumatera / Sumatera
Pulau
Island
Jawa / Java
Kalimantan / Kalimantan
Manufaktur /
Manufacture
Pendapatan dari
pelanggan eksternal
Pendapatan antar
segmen
Pendapatan bunga
Beban bunga
Penyusutan dan
amortisasi
Laba (rugi ) bersih
segmen dilaporkan
Aset segmen dilaporkan
Belanja untuk aset tidak
lancar dilaporkan
Liabilitas segmen
dilaporkan
Sumatera/
Jenis Usaha/
Type of business
Sumatera
Distribusi /
Distribution
Retail / Retail
Lainnya /
Others
Total / Total
153.557.373.389
1.935.003.276.657
2.210.354.594.316
49.158.744.023
4.348.073.988.385
1.023.143.218.981
2.378.946.225
6.485.409.952
90.034.399.484
803.053.871
1.718.383.944
501.411.443
1.435.847.688
19.995.791
-
1.113.177.618.465
3.703.407.330
9.639.641.584
17.513.098.158
2.327.502.077
10.428.292.814
694.189.099
30.963.082.148
116.739.897.144
1.014.253.513.999
45.564.813.491
777.720.621.494
50.611.874.645
659.477.819.493
1.632.568.980
20.487.593.902
214.549.154.260
2.471.939.548.890
63.334.207.182
5.172.993.175
19.127.711.037
1.395.165.325
89.030.076.719
314.680.937.979
220.552.694.004
307.320.693.503
5.030.534.422
847.584.859.908
85
200
Revenue from
external cutomers
Revenue per
segment
Interest income
Interest expense
Depreciation and
amortization
Segmented report
profit and loss net
Segemntes assets
Ourchasing for non
current assets
Segmented report
liabilities
Distribusi /
Distribution
Lainnya /
Others
Total / Total
198.608.647.160
1.608.418.542.254
1.888.725.966.934
38.949.519.181
3.734.702.675.529
843.765.260.932
1.130.215.470
4.019.553.661
94.411.922.923
522.426.296
1.682.761.213
919.069.415
1.170.088.512
13.650.527
-
938.177.183.855
2.585.361.708
6.872.403.386
16.904.981.156
2.445.213.533
10.622.778.940
723.515.500
30.696.489.129
151.934.796.474
1.150.327.589.300
23.678.017.241
424.605.724.189
30.149.627.276
489.437.992.255
1.556.387
11.976.275.042
205.763.997.378
2.076.347.580.786
40.308.308.080
11.723.768.000
28.952.422.526
817.344.128
81.801.842.734
207.496.908.436
172.451.550.817
250.808.749.823
4.056.682.043
634.813.891.119
195.476.452.961
158.425.373.165
183.652.037.485
4.182.875.668
541.736.739.279
Pendapatan
Jumlah pendapatan untuk segmen
dilaporkan
Pendapatan lainnya
Eliminasi pendapatan antar segmen
Pendapatan etintas
Laba Rugi
Jumlah pendapatan untuk segmen
dilaporkan
Pendapatan (Rugi) lainnya
Eliminasi pendapatan antar segmen
Laba rugi Entitas Induk
Aset
Jumlah aset untuk Segmen
dilaporkan
Aset lainnya
Eliminasi piutang antar segmen
Jumlah aset Entitas
Liabilitas
Jumlah liabilitas untuk Segmen
dilaporkan
Liabilitas lainnya
Jumlah aset Entitas
31 / 12 / 2013
31 / 12 / 2012
5.412.092.862.827
49.158.744.023
(1.113.177.618.465)
4.348.073.988.385
4.633.468.765.983
38.949.519.181
(938.177.183.855)
3.734.241.101.309
31 / 12 / 2013
31 / 12 / 2012
202.948.677.248
1.632.568.980
9.967.908.032
214.549.154.260
201.039.739.809
1.556.387
4.722.701.182
205.763.997.378
31 / 12 / 2013
31 / 12 / 2012
3.131.910.104.277
20.487.593.904
(680.458.149.291)
2.471.939.548.888
2.390.199.213.660
16.276.118.148
(330.127.751.023)
2.076.347.580.785
31 / 12 / 2013
31 / 12 / 2012
842.554.325.486
5.030.534.422
847.584.859.908
630.631.015.451
4.182.875.668
634.813.891.119
Revenue from
external cutomers
Revenue per
segment
Interest income
Interest expense
Depreciation and
amortization
Segmented report
profit and loss net
Segemntes assets
Ourchasing for non
current assets
Segmented report
liabilities
Segmented report
liabilities
Revenue
Total revenue to segmented
report
Others income
Eliminated revenue inter segment
Entity revenue
Profit and loss
Total revenue to segmented
report
Others income
Eliminated revenue inter segment
Profit and loss holdings
Assets
Total assets to segmented
report
Others assets
Eliminated receivable inter segment
Tatal assets Entity
Liabilities
Total liabilities to segmented
report
Others liabilities
Total Assets Entity
86
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
201
Indonesia
Timor Leste
India
China
Inggris
Belanda
Amerika Serikat
Jepang
German
Malaysia
Afganistan
Australia
Singapore
Irlandia
Afrika Selatan
Lain-lain (di bawah Rp
1.000.000.000)
Jumlah
31 / 12 / 2013
Rp
4.145.116.326.216
70.457.199.196
28.762.419.424
28.514.514.408
23.346.766.150
22.157.627.464
10.721.307.177
4.144.956.325
2.890.206.650
2.167.781.500
1.935.103.298
1.867.659.150
379.312.650
215.360.250
-
31 / 12 / 2012
Rp
3.588.272.823.021
11.109.070.060
25.885.633.645
26.109.679.776
7.167.780.625
32.537.789.450
12.305.373.313
6.624.479.692
4.331.447.625
476.640.000
1.806.422.616
1.533.837.900
1.890.632.900
5.370.453.367
1.447.911.050
5.397.448.527
0,12
7.847.766.269
0,21
4.348.073.988.385
100,00
3.734.241.101.309
100,00
US$
SG$
US$
US$
EUR
840.223,98
2.718,96
9.244.980,65
3.206.152,18
7.154,67
10.241.490.074
26.178.505
112.687.069.087
122.954.737.666
39.079.788.933
120.352.329
39.200.141.262
31 / 12 / 2012
Mata uang
Ekuivalen
Asing /
Rupiah /
Foreign
Equivalent IDR
Currency
598.609,75
3.441.901,93
2.378.090,31
15.288
5.788.556.238
33.283.191.650
39.832.776.888
22.996.133.259
195.837.140
23.191.970.399
16.640.806.489
87
202
Indonesia
Timor Leste
India
China
Inggris
Belanda
Amerika Serikat
Jepang
German
Malaysia
Afganistan
Australia
Singapore
Irlandia
Afrika Selatan
Others (Below
Rp 1,000,000,000)
Total
83.754.596.404
%
96,09
0,30
0,69
0,70
0,19
0,87
0,33
0,18
0,12
0,00
0,05
0,04
0,05
0,14
0,04
Monetary Assets
Cash and cash
equivalent
Account receivables
Monetary liabilities
Account payables
Total monetary (assets)
liabilities - net
31 Desember 2013
Aset Keuangan
Kas dan setara kas
Piutang usaha pihak
berelasi
Piutang usaha pihak
ketiga
Piutang lain-lain jangka
Panjang
Piutang lain-lain
Liabilitas Keuangan
Utang usaha pihak
ketiga
Utang usaha pihak
berelasi
Utang lain-lain
Biaya yang masih harus
dibayar
Utang bank
Jumlah Liabilitas
Keuangan
Jumlah
/
Total
Pinjaman dan
Piutang /
Loans and
Receivables
Aset
Keuangan
Tersedia
untuk Dijual
/ Available for
Sale
Aset Keuangan
Lainnya
/ Other Financial
Assets
394.149.909.832
394.149.909.832
61.534.147.809
61.534.147.809
485.042.276.146
485.042.276.146
523.375.893
7.644.556.388
523.375.893
7.644.556.388
948.894.266.068
948.894.266.068
456.169.891.947
456.169.891.947
21.721.859.363
46.371.989.506
21.721.859.363
46.371.989.506
117.961.455.449
47.375.830.919
117.961.455.449
47.375.830.919
Financial Liabilities
Third Parties Account
Payables
Related Parties Account
Payables
Others Payables
Accrued
expense
Bank loan
689.601.027.184
689.601.027.184
88
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
203
Jumlah
/
Total
Pinjaman dan
Piutang /
Loans and
Receivables
Nilai Wajar
Diakui
Melalui
Laporan
Laba Rugi /
Fair Value
Recognized
Through
Profit and
Loss
Aset
Keuangan
Tersedia
untuk Dijual
/ Available for
Sale
Aset Keuangan
Lainnya
/ Other Financial
Assets
31 Desember 2012
Aset Keuangan
Kas dan setara kas
Deposito
Piutang usaha pihak
berelasi
Piutang usaha pihak
ketiga
Piutang lain-lain
Piutang lain-lain jangka
Panjang
Liabilitas Keuangan
Utang Bank
Utang usaha pihak
berelasi
Utang usaha pihak
ketiga
Liabilitas lancar lain-lain
Biaya yang masih harus
dibayar
Jumlah Liabilitas
Keuangan
316.497.879.806
-
103.770.489.171
103.770.489.171
354.958.026.078
5.738.392.231
354.958.026.078
5.738.392.231
1.141.880.429
782.106.667.715
1.141.880.429
782.106.667.715
17.377.108.766
17.377.108.766
36.884.377.032
36.884.377.032
304.248.660.515
-
304.248.660.515
-
91.281.052.262
91.281.052.262
449.791.198.575
449.791.198.575
Financial Assets
Cash and Cash Equivalent
Deposits
Related Parties Account
Receivables
Third Parties Account
Receivables
Other Receivables
Long Term
Receivables
Financial Liabilities
Bank Payable
Related Parties Account
Payables
Third Parties Account
Payables
Other Current Liabilities
Accrued
expense
Total Financial
Liabilities
Risiko likuiditas,
Entitas menetapkan risiko
kolektibilitas dari piutang usaha seperti yang dijelaskan
di atas, sehingga mengalami kesulitan dalam memenuhi
kewajiban yang terkait dengan liabilitas keuangan.
89
204
31 / 12 / 2013
Piutang usaha
Piutang lain-lain
31 / 12 / 2012
546.576.423.955
7.644.556.388
458.728.515.248
6.880.272.661
Account receivable
Others receivable
90
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
205
Risiko Likuiditas
Liquidity Risk
Utang bank
Utang usaha
Utang pajak
Uang muka penjualan
Biaya yang masih harus dibayar
31 / 12 / 2013
31 / 12 / 2012
47.375.830.919
477.891.751.309
52.708.653.939
2.077.643.896
117.961.455.449
17.377.108.766
341.133.037.547
46.608.327.874
1.665.285.810
91.281.052.262
Bank loan
Account payable
Tax payable
Unearned revenue
Accrued expense
Risiko Pasar
Market Risk
Risiko dimana nilai wajar atau arus kas masa depan suatu
instrumen keuangan akan berfluktuasi karena perubahan
harga pasar. Risiko pasar meliputi tiga jenis yaitu: risiko
mata uang asing, risiko suku bunga dan risiko harga
lainnya seperti risiko perubahan harga komoditas.
91
206
31 / 12 / 2013
Euro Eropa
10.085.204,63
(3.206.152,18)
6.879.052,45
(7.154,67)
(7.154,67)
USD
31 / 12 / 2012
Euro Eropa
4.040.511,68
(2.378.090,31)
1.662.421,37
(15.288)
(15.288)
Monetary assets
Monetary liabilities
Risiko Permodalan
Capital Risk
92
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
207
31 / 12 / 2013
Utang bank
Utang Sewa Guna Usaha
Total utang yang berbunga
Total ekuitas yang dapat
diatribusikan kepada pemilik
entitas induk
Rasio utang berbunga terhadap
ekuitas
31 / 12 / 2012
47.375.830.919
3.608.772.797
50.984.603.716
17.377.108.766
10.476.658.718
27.853.767.484
1.608.224.645.678
1.426.496.822.081
3,17%
1,95%
Bank loan
Lease
Total
Total equity attributable to
owners of
the entity
Liability to equity
ratio
Risiko Perekonomian
Economic risk
93
208
94
Laporan Tahunan 2013 PT Kimia Farma (Persero) Tbk
PT Kimia Farma (Persero) Tbk Annual Report 2013
209
5 Maret 2014
5 March 2014
Dewan Komisaris
Board of Commissioners
Direksi
Board of Directors
Rusdi Rosman
Direktur Utama
President Director
Arief Budiman
Direktur Keuangan
Finance Director
210
Jisman Siagian
Direktur Operasi & Supply
Chain
Operation & Supply Chain
Director
M. Wahyuli Syafari
Direktur Riset &
Pengembangan Bisnis
Research & Business
Development Director
Pujianto
Direktur Umum & Human
Capital
General Affair & Human Capital
Director
Alamat Pabrik /
Plant Addresses
Plant Jakarta
Jl.Rawagelam V No.1
Kawasan Industri Pulogadung
Jakarta 73930
Telp. (021) 460 9354 (Hunting)
Fax. (021) 460 3143
Plant Bandung
Plant Semarang
Jl. Simongan PO BOX 1206
Semarang 50147
Telp. (024) 760 4060, 760 5273
Fax. (024) 760 5365
Plant Watudakon
Jl. Ds. Jombok, Kec. Kesamben,
Kab. Jombang
PO BOX 126 Mojokerto 61301
Telp. (0321) 397 3002
Fax. (0321) 397 3003